JP4350435B2 - Hydrophilic adhesive composition - Google Patents
Hydrophilic adhesive composition Download PDFInfo
- Publication number
- JP4350435B2 JP4350435B2 JP2003176384A JP2003176384A JP4350435B2 JP 4350435 B2 JP4350435 B2 JP 4350435B2 JP 2003176384 A JP2003176384 A JP 2003176384A JP 2003176384 A JP2003176384 A JP 2003176384A JP 4350435 B2 JP4350435 B2 JP 4350435B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- adhesive composition
- hydrophilic
- sensitive adhesive
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 75
- 230000001070 adhesive effect Effects 0.000 title claims description 27
- 239000000853 adhesive Substances 0.000 title claims description 26
- -1 aluminum compound Chemical class 0.000 claims description 64
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 57
- 229920001577 copolymer Polymers 0.000 claims description 31
- 239000000178 monomer Substances 0.000 claims description 28
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 20
- 150000003950 cyclic amides Chemical class 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- 150000005846 sugar alcohols Polymers 0.000 claims description 16
- 229910052782 aluminium Inorganic materials 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 claims description 9
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 claims description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 claims description 6
- 238000007334 copolymerization reaction Methods 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 229920002125 Sokalan® Polymers 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 229940091250 magnesium supplement Drugs 0.000 description 10
- RQAKESSLMFZVMC-UHFFFAOYSA-N n-ethenylacetamide Chemical compound CC(=O)NC=C RQAKESSLMFZVMC-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 239000004584 polyacrylic acid Substances 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 7
- 229960004889 salicylic acid Drugs 0.000 description 7
- 229920002554 vinyl polymer Polymers 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 6
- 239000003431 cross linking reagent Substances 0.000 description 6
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 6
- 229940043276 diisopropanolamine Drugs 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 5
- UBPXWZDJZFZKGH-UHFFFAOYSA-N 1-ethenyl-3-methylpyrrolidin-2-one Chemical compound CC1CCN(C=C)C1=O UBPXWZDJZFZKGH-UHFFFAOYSA-N 0.000 description 5
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 5
- 241000723346 Cinnamomum camphora Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000004166 Lanolin Substances 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 229940024545 aluminum hydroxide Drugs 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 229960000846 camphor Drugs 0.000 description 5
- 229930008380 camphor Natural products 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 229940039717 lanolin Drugs 0.000 description 5
- 235000019388 lanolin Nutrition 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229940083542 sodium Drugs 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- 229960000859 tulobuterol Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 229960005434 oxybutynin Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229940047670 sodium acrylate Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- HQGPZXPTJWUDQR-UHFFFAOYSA-N 1-ethenyl-5-methylpyrrolidin-2-one Chemical compound CC1CCC(=O)N1C=C HQGPZXPTJWUDQR-UHFFFAOYSA-N 0.000 description 3
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- 229960005274 benzocaine Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 3
- 229960001193 diclofenac sodium Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229910001701 hydrotalcite Inorganic materials 0.000 description 3
- 229960001545 hydrotalcite Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 2
- CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- RNIHAPSVIGPAFF-UHFFFAOYSA-N Acrylamide-acrylic acid resin Chemical compound NC(=O)C=C.OC(=O)C=C RNIHAPSVIGPAFF-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 241000772415 Neovison vison Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 239000004204 candelilla wax Substances 0.000 description 2
- 235000013868 candelilla wax Nutrition 0.000 description 2
- 229940073532 candelilla wax Drugs 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 229940082483 carnauba wax Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- 229960003338 crotamiton Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- WEHZQLDFDZDFRZ-UHFFFAOYSA-N ethylamino benzoate Chemical compound CCNOC(=O)C1=CC=CC=C1 WEHZQLDFDZDFRZ-UHFFFAOYSA-N 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- JAYKNMXVTNKTCW-UHFFFAOYSA-N magnesium;propane-1,2,3-triol Chemical compound [Mg].OCC(O)CO JAYKNMXVTNKTCW-UHFFFAOYSA-N 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- PZYDAVFRVJXFHS-UHFFFAOYSA-N n-cyclohexyl-2-pyrrolidone Chemical compound O=C1CCCN1C1CCCCC1 PZYDAVFRVJXFHS-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- QJBZDBLBQWFTPZ-UHFFFAOYSA-N pyrrolnitrin Chemical compound [O-][N+](=O)C1=C(Cl)C=CC=C1C1=CNC=C1Cl QJBZDBLBQWFTPZ-UHFFFAOYSA-N 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 229960003070 tioxolone Drugs 0.000 description 2
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 2
- 229960004880 tolnaftate Drugs 0.000 description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- YSTPAHQEHQSRJD-SECBINFHSA-N (-)-piperitone Chemical compound CC(C)[C@H]1CCC(C)=CC1=O YSTPAHQEHQSRJD-SECBINFHSA-N 0.000 description 1
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- WHOZNOZYMBRCBL-OUKQBFOZSA-N (2E)-2-Tetradecenal Chemical compound CCCCCCCCCCC\C=C\C=O WHOZNOZYMBRCBL-OUKQBFOZSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- ZPPBASOODYCKDP-YZZSNFJZSA-N (4r,4ar,7s,7ar,12bs)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrochloride Chemical compound Cl.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC ZPPBASOODYCKDP-YZZSNFJZSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BFUXUGOZJVHVMR-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1CNS(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C21 BFUXUGOZJVHVMR-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- NAGSMIOYEJTYQT-UHFFFAOYSA-N 1-ethenyl-3,3,5-trimethylpyrrolidin-2-one Chemical compound CC1CC(C)(C)C(=O)N1C=C NAGSMIOYEJTYQT-UHFFFAOYSA-N 0.000 description 1
- PBGPBHYPCGDFEZ-UHFFFAOYSA-N 1-ethenylpiperidin-2-one Chemical compound C=CN1CCCCC1=O PBGPBHYPCGDFEZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IVIDDMGBRCPGLJ-UHFFFAOYSA-N 2,3-bis(oxiran-2-ylmethoxy)propan-1-ol Chemical compound C1OC1COC(CO)COCC1CO1 IVIDDMGBRCPGLJ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- JLZIIHMTTRXXIN-UHFFFAOYSA-N 2-(2-hydroxy-4-methoxybenzoyl)benzoic acid Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1C(O)=O JLZIIHMTTRXXIN-UHFFFAOYSA-N 0.000 description 1
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- HDPLHDGYGLENEI-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COCC1CO1 HDPLHDGYGLENEI-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ZVTDEEBSWIQAFJ-KHPPLWFESA-N 2-hydroxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)O ZVTDEEBSWIQAFJ-KHPPLWFESA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- WZUKKIPWIPZMAS-UHFFFAOYSA-K Ammonium alum Chemical compound [NH4+].O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O WZUKKIPWIPZMAS-UHFFFAOYSA-K 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 239000004593 Epoxy Chemical class 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- AGJUUQSLGVCRQA-SWOUQTJZSA-N Fungichromin Chemical compound CCCCC[C@@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)[C@@H](O)[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O AGJUUQSLGVCRQA-SWOUQTJZSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000756137 Hemerocallis Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- AGJUUQSLGVCRQA-UHFFFAOYSA-N Pentamycin Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O AGJUUQSLGVCRQA-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- UGGAILYEBCSZIV-ITJSPEIASA-N Siccanin Chemical compound C1CCC(C)(C)[C@@H]2CC[C@]3(C)OC4=CC(C)=CC(O)=C4[C@H]4[C@@H]3[C@@]21CO4 UGGAILYEBCSZIV-ITJSPEIASA-N 0.000 description 1
- UGGAILYEBCSZIV-UHFFFAOYSA-N Siccanin Natural products C1CCC(C)(C)C2CCC3(C)OC4=CC(C)=CC(O)=C4C4C3C21CO4 UGGAILYEBCSZIV-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000005843 Thiram Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- ZYPGADGCNXOUJP-CXVPHVKISA-N Variotin Chemical compound CCCC[C@@H](O)\C=C(/C)\C=C\C=C\C(=O)N1CCCC1=O ZYPGADGCNXOUJP-CXVPHVKISA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- YMOONIIMQBGTDU-VOTSOKGWSA-N [(e)-2-bromoethenyl]benzene Chemical compound Br\C=C\C1=CC=CC=C1 YMOONIIMQBGTDU-VOTSOKGWSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- WPZSJJJTNREFSV-UHFFFAOYSA-N [Zn].[O-][N+]1=CC=CC=C1S Chemical compound [Zn].[O-][N+]1=CC=CC=C1S WPZSJJJTNREFSV-UHFFFAOYSA-N 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 229940114077 acrylic acid Drugs 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000011124 aluminium ammonium sulphate Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- LCPUDZUWZDSKMX-UHFFFAOYSA-K azane;hydrogen sulfate;iron(3+);sulfate;dodecahydrate Chemical compound [NH4+].O.O.O.O.O.O.O.O.O.O.O.O.[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCPUDZUWZDSKMX-UHFFFAOYSA-K 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical class C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UTMTYYKGLQURCK-UHFFFAOYSA-N butane-1,3-diol;propane-1,2,3-triol Chemical compound CC(O)CCO.OCC(O)CO UTMTYYKGLQURCK-UHFFFAOYSA-N 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 229940070400 clinidine Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 229960004138 cyclobarbital Drugs 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- HFBYLYCMISIEMM-FFHNEAJVSA-N dihydrocodeine phosphate Chemical compound OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC HFBYLYCMISIEMM-FFHNEAJVSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- ZYPGADGCNXOUJP-UHFFFAOYSA-N dl-Variotin Natural products CCCCC(O)C=C(C)C=CC=CC(=O)N1CCCC1=O ZYPGADGCNXOUJP-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000005293 duran Substances 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- ZFSXZJXLKAJIGS-UHFFFAOYSA-N halocarban Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=CC(Cl)=CC=2)=C1 ZFSXZJXLKAJIGS-UHFFFAOYSA-N 0.000 description 1
- 229950006625 halocarban Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- WYVGZXIHGGQSQN-UHFFFAOYSA-N hexadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCCCC(O)=O WYVGZXIHGGQSQN-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 229950008838 indenolol Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 229960004007 isoconazole nitrate Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940063559 methacrylic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- ZQMHJBXHRFJKOT-UHFFFAOYSA-N methyl 2-[(1-methoxy-2-methyl-1-oxopropan-2-yl)diazenyl]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)N=NC(C)(C)C(=O)OC ZQMHJBXHRFJKOT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940067137 musk ketone Drugs 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960004031 omoconazole Drugs 0.000 description 1
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229930006948 p-menthane-3,8-diol Natural products 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229960000339 pentamycin Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940044654 phenolsulfonic acid Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012673 precipitation polymerization Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
- 229960003402 propatylnitrate Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 229960002132 pyrrolnitrin Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229950008379 siccanin Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- RBNWAMSGVWEHFP-WAAGHKOSSA-N terpin Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(O)CC1 RBNWAMSGVWEHFP-WAAGHKOSSA-N 0.000 description 1
- 229950010257 terpin Drugs 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 1
- 229960002447 thiram Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- CVNKFOIOZXAFBO-UHFFFAOYSA-J tin(4+);tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Sn+4] CVNKFOIOZXAFBO-UHFFFAOYSA-J 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Adhesives Or Adhesive Processes (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、環状アミドモノマーと(メタ)アクリル酸とからなる共重合体を含む親水性粘着剤組成物に関し、より詳しくは、薬効成分を高濃度の多価アルコールに分散もしくは溶解して含ませることにより、薬物の放出特性および粘着性に優れる安全性の高い経皮吸収型外用剤用の親水性粘着剤組成物に関する。
【0002】
【従来の技術】
近年、医療用としての口膣粘膜用製剤、経皮吸収用製剤などにおいて、多価アルコールなどのアルコール類が、薬物の溶解性および経皮吸収性を高めることが確かめられてきており、このようなアルコール類を貼付剤に高濃度で含有させることが課題とされている。
【0003】
一般に経皮吸収製剤は、プラスター剤、テープ剤などの非水系製剤と、パップ剤などの含水系製剤との2種類に分けられる。
【0004】
非水系製剤の粘着剤には、アクリル系またはゴム系のものが用いられているが、薬物の経皮吸収性は良好であるものの、その粘着性の強さから皮膚に対する刺激性が大きく、特に繰り返し貼る必要のある薬物には適用が困難であった。また、粘着剤に親水性がないために汗や体液などにより剥がれやすく、皮膚と製剤との間に隙間が生じ、結果として薬物の吸収性が落ちるという問題がある。さらに、アクリル系の高分子には依然として残留モノマーの毒性の問題が残されており、とりわけ皮膚に貼付する場合、残留モノマーによる皮膚刺激性が生ずる場合がある。
【0005】
一方含水系製剤は、一般にトラガントガム、アラビアゴム、カラギーナン、デュランガム、アルギン酸ナトリウム、マンナン、ゼラチンなどの天然の水溶性高分子、または、ポリアクリル酸(塩)、ポリメタクリル酸(塩)、ポリビニルアルコール、ポリアクリルアミドなどの合成高分子を用い、これに多価アルコールなどの保湿剤等を配合して構成されている。これら粘着剤基材は親水性であるために皮膚への刺激性は少なく、長期の適用に適しているといえるが、粘着性に乏しく、また基本的に皮膚から吸収される薬物は親油性のものが多いため、水の含有量が多い本製剤中においては薬物が溶解しにくいことから、結果として吸収性が劣っていた。さらに加水分解されやすい薬物等には、経時による薬物の安定性の確保が困難であった。
【0006】
かかる問題を回避するため、たとえば、10%水溶液粘度が100〜1000cpsの固形または粉末状のポリアクリル酸を多価アルコールに溶解した粘着剤基材が提案されている(特許文献1)。ポリアクリル酸は、親水性があり刺激性は少ないことが予想できるものの、多価アルコールに溶解した際の増粘性は低く、結果として粘着力を高くすることは困難であった。また、ポリアクリル酸はアニオン性の高分子であるため、薬効成分がカチオン性の場合、イオンコンプレックスを形成し薬物の放出性が著しく悪くなっていた。皮膚から吸収される薬物の中にはカチオン性のものが多く、このことは大きな欠点となっていた。
【0007】
また、ポリ−N−ビニルアミドを薬物貯蔵層に含有せしめたことを特徴とする経皮投与用デバイスが提案されている(特許文献2)。しかしながら、このデバイス中のポリ−N−ピロリドンは、薬効成分の貯蔵層に用いられるもので、粘着剤としての役割は果たしていない。したがって、皮膚と薬物貯蔵層との間にさらに粘着層が存在するため、製造が困難であり、また粘着層が薬効成分の吸収性に影響を与えていた。
【0008】
さらに、すでに経皮吸収型外用剤用の粘着剤としてアクリル酸2−エチルヘキシル・ビニルピロリドン共重合溶液が使用されている(非特許文献1)。しかしながら、該粘着剤は、水との親和性が著しく低いため刺激性があり、また製剤化の過程において酢酸エチルなどの低沸点溶剤を用いる必要があり、環境に対して負荷のかかるものであった。
【0009】
【特許文献1】
特開平6−135828号公報
【特許文献2】
特表平8−512054号公報
【非特許文献1】
『医薬品添加物辞典 2000』薬事日報社 1頁
【0010】
【発明が解決しようとする課題】
本発明は、粘着性の良好な親水性吸着剤を提供することを課題とする。
【0011】
また、本発明は、被着体への粘着性が良好であり、皮膚への刺激性が少なく、しかも離しょう液が生じることなく、単純な組成で調整が容易な薬効成分の経皮吸収性の高い親水性粘着剤組成物を提供することを課題とする。
【0012】
【課題を解決するための手段】
本発明者らは、上記の様な実情に鑑み、鋭意検討を重ねた結果、環状アミドモノマー単位と(メタ)アクリル酸単位とを含む共重合体(環状アミドモノマー/(メタ)アクリル酸共重合体)は、その構成単位がアミド基およびカルボキシル基の親水性官能基を有することから、粘着層の親水性が向上し、皮膚面に分泌される水分を吸収するため、貼付剤の皮膚密着性を維持し、また外界の水蒸気との間に平衡状態が成立し、皮膚のむれおよびカブレを防止することができることを見出した。また、環状アミドモノマーはノニオン性であることから、カチオン性の薬物との反応によりイオンコンプレックスを生成する確率が減り、より広範囲の薬効成分に対し、優れた経皮吸収性を有する可能性があることを見出した。さらに、上記共重合体と、アルミニウム化合物と、多価アルコールとを含む親水性粘着剤組成物が優れた粘着性を有することを見いだし、本発明を完成した。
【0013】
すなわち、本発明は以下の項目からなる。
(1)下記一般式(I)で表される繰り返し単位および下記一般式(II)で表される繰り返し単位のみからなる共重合体と、メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウム、水酸化アルミニウムおよびジヒドロキシアルミニウムアミノアセテートからなる群より選ばれる少なくとも1種のアルミニウム化合物と、多価アルコールとを含み、前記共重合体における前記式(I)で表される繰り返し単位と前記式(II)で表される繰り返し単位との共重合比が重量比で80/20〜20/80であることを特徴とする親水性粘着剤組成物;
【0014】
【化4】
【0015】
【化5】
【0016】
(式中、R1は置換基を有していてもよい炭素数3〜7のアルキレン鎖を示し、R2は水素原子またはメチル基を示す。複数の繰り返し単位におけるR1およびR2は、それぞれ同一でもよく、異なっていてもよい。)
(2)下記一般式(III)で表される環状アミドモノマーおよび(メタ)アクリル酸のみからなるモノマー混合物を重合させて得られた共重合体と、メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウム、水酸化アルミニウムおよびジヒドロキシアルミニウムアミノアセテートからなる群より選ばれる少なくとも1種のアルミニウム化合物と、多価アルコールとを含み、前記共重合体における前記環状アミドモノマーと前記(メタ)アクリル酸との共重合比が重量比で80/20〜20/80であることを特徴とする親水性粘着剤組成物;
【0017】
【化6】
【0018】
(式中、R3は置換基を有していてもよい炭素数3〜7のアルキレン鎖を示す。)
(3)薬効成分をさらに含むことを特徴とする(1)〜(2)のいずれかに記載の親水性粘着剤組成物。
(4)水をさらに含むことを特徴とする(1)〜(3)のいずれかに記載の親水性粘着剤組成物。
(5)アルカリ性物質をさらに含むことを特徴とする(4)に記載の親水性粘着剤組成物。
(6)酸をさらに含むことを特徴とする(4)または(5)に記載の親水性粘着剤組成物。
(7)上記酸がオキシカルボン酸であることを特徴とする(6)に記載の親水性粘着剤組成物。
(8)多価アルコール以外の有機溶剤をさらに含むことを特徴とする(1)〜(7)のいずれかに記載の親水性粘着剤組成物。
(9)上記有機溶剤がアルキルピロリドンであることを特徴とする(8)に記載の親水性粘着剤組成物。
(10)(1)〜(9)のいずれかに記載の親水性粘着剤組成物を用いることを特徴とする貼付剤。
(11)(3)〜(9)のいずれかに記載の親水性粘着剤組成物を用いることを特徴とする経皮吸収型外用剤。
【0019】
【発明の実施の形態】
本発明の親水性粘着剤組成物は、下記一般式(I)および(II)で表される繰り返し単位を含む環状アミドモノマー/(メタ)アクリル酸共重合体(成分A)と、アルミニウム化合物(成分C)と、多価アルコール(成分B)とを含む。さらに、薬効成分(成分D)を含ませることがより有効である。
【0020】
【化7】
【0021】
【化8】
【0022】
式中、R1は置換基を有していてもよい炭素数3〜7のアルキレン鎖を示し、R2は水素原子またはメチル基を示す。複数の繰り返し単位におけるR1およびR2は、同一でもよく、異なっていてもよい。
【0023】
本発明で用いられる成分Aは、親水性粘着剤組成物の全量に対して0.5〜30質量%(以下単に%という)の範囲で使用することが好ましく、さらに好ましくは2%〜20%の範囲がよい。成分Aの含有量が0.5%未満の場合には、粘着層から離しょう液が生成して不均一となり、30%を超えると成形時の粘着剤組成物の粘度が上昇するため、成形および他の成分の混合が困難になることがある。
【0024】
成分Aは、通常、下記一般式(III)で表される環状アミドモノマーと、(メタ)アクリル酸とを共重合させることにより得られる。
【0025】
【化9】
【0026】
式中、R3は置換基を有していてもよい炭素数3〜7のアルキレン鎖を示す。
上記環状アミドモノマーとしては、たとえば、N−ビニルピロリドン、N−ビニル−3−メチルピロリドン、N−ビニル−5−メチルピロリドン、N−ビニル−3,3,5−トリメチルピロリドン、N−ビニルピペリドン、N−ビニルカプロラクタム、N−ビニルカプリルラクタム等が挙げられる。
【0027】
本発明で用いられる(メタ)アクリル酸とは、アクリル酸またはメタクリル酸を指す。
【0028】
上記環状アミドモノマーおよび(メタ)アクリル酸は、それぞれ単独で用いても、2種以上を組み合わせて用いてもよい。また、環状アミドモノマーと(メタ)アクリル酸との共重合比は、好ましくは80/20〜20/80、より好ましくは70/30〜30/70である。
【0029】
本発明で用いられる成分Aは、粘着性の向上、薬物を安定に含有させることなどを目的として、他のモノマー成分、たとえば(メタ)アクリル酸のエステルなどを親水性の阻害にならない程度に共重合させることもできる。この場合、環状アミドモノマーおよび(メタ)アクリル酸成分が、モノマー全体の80質量%以上含まれていることが好ましく、90質量%以上含まれていることがより好ましい。通常は、他のモノマーを用いる必要はない。
【0030】
成分Aは、所定の割合のモノマーを、公知の方法で共重合させて製造することができる。たとえば、水溶液重合、逆層懸濁重合、沈殿析出重合などが適用できる。重合が終了すると、粘性液体、寒天状または粉末状の生成物が得られる。さらに、粘性液体または寒天状の生成物は、脱水乾燥することによって粉末化することができる。このようにして得られた成分Aを本発明の親水性粘着剤組成物に添加する場合、粉末状で添加することが好ましいが、粘性液体のポリマー濃度、多価アルコール(成分B)の添加割合によっては、粘性液体のまま供することもできる。
【0031】
成分Aとしては、成分Aの(メタ)アクリル酸部分をアルカリで中和した重合体の10質量%溶液の粘度が、6〜2000mPa・sであることが好ましい。
【0032】
上記粘度の具体的な測定手順としては、まず、乾燥した共重合体(成分A)20gをイソプロパノール/水=1/1(容量比)に溶解して200gとし、次いで10質量%のアルカリ溶液で(メタ)アクリル酸部分を中和し、中和した溶液を25℃に加温した後、ブルックフィールド型粘度計を用いて回転数20rpmで粘度を測定する。
【0033】
本発明の親水性粘着剤組成物には、粘着剤の保型性および粘着性を得るために多価アルコール(成分B)を添加する。成分Bは、親水性粘着剤組成物中での薬物の溶解性および活量を高め、皮膚への移行性を向上させる目的でも有用である。
【0034】
成分Bとしては、特に制限されないが、エチレングリコール、プロピレングリコール、1,3−ブチレングリコール、ジエチレングリコール、トリエチレングリコール、1,4−ブチレングリコール(2価アルコール)、グリセリン、トリオキシイソブタン(3価アルコール)、エリトリット、ペンタエリトリット(4価アルコール)、キシリット、アドニット(5価アルコール)、アロズルシット、ソルビトール、ソルビット液、マンニトール(6価アルコール)、ポリグリセリン、ジプロピレングリコールなどが挙げられる。
【0035】
なお、本明細書における多価アルコールとは、その分子内のOH基の総分子量が分子全体の分子量の50分の1以上であるものを指す。50分の1未満であると、式(I)で表されるポリマーとの親和性が悪くなることがある。これらの中ではグリセリンが、その安全性および環状アミドモノマー/(メタ)アクリル酸共重合体との親和性の面から特に好ましい。成分Bは単独で用いても、2種以上を組み合わせて用いてもよい。
【0036】
成分Bは、親水性粘着剤組成物の全量に対して20〜99質量%の範囲、好ましくは40〜90質量%の範囲で添加される。成分Bの添加量が20質量%未満の場合、99質量%を超える場合の何れの場合も、成分Aによる増粘効果が発現しにくくなり、粘着層の充分な保型性が得られ難くなることがある。
【0037】
本発明の親水性粘着剤組成物には、多価アルコール類以外の有機溶剤を添加することができる。このような有機溶剤としては、たとえば
メタノール、エタノール、プロパノール、ベンジルアルコール、フェネチルアルコール、イソプロピルアルコール、イソブチルアルコール、ヘキシルアルコール、2−エチルヘキサノール、シクロヘキサノール、オクチルアルコール、ブタノール、ペンタノール、アルコキシエタノール(具体的には、メトキシエタノール、エトキシエタノール、ブトキシエタノール等)などの1価アルコール;
アセトン、メチルエチルケトンなどのケトン類;
ジオキサン、ジメチルホルムアミド、ジメチルアセトアミド、N−メチル−2−ピロリドン、N−エチル−2−ピロリドン、N−シクロヘキシル−2−ピロリドン、ジメチルスルホキシドなどの水と混和しうる有機溶剤;および
酢酸エチル、クロタミトンなどの水と混和しない有機溶剤が挙げられる。これらの中でも、特にN−メチル−2−ピロリドン、N−エチル−2−ピロリドン、N−シクロヘキシル−2−ピロリドンなどのアルキルピロリドンが、薬物の溶解性および活量を高め、さらには環状アミドモノマー/(メタ)アクリル酸共重合体との親和性の面から好ましい。
【0038】
上記有機溶剤は、親水性粘着剤組成物の全量に対して0.01〜50質量%の範囲、好ましくは0.5〜30質量%の範囲で添加される。上記有機溶剤の添加量が0.01質量%未満の場合には、薬物の溶解性が低下し、製剤中で薬物が析出することがあり、50質量%を超えると溶剤のしみ出しが起きて、薬剤として使用できないことがある。
【0039】
本発明の親水性粘着剤組成物には、ゲルの保型性維持および「糊残り」防止を目的としてアルミニウム化合物(成分C)を架橋剤として添加する。
【0040】
成分Cとしては、たとえば、塩化アルミニウム、カリミョウバン、アンモニウムミョウバン、硝酸アルミニウム、硫酸アルミニウム、EDTA−アルミニウム、水酸化アルミニウム・炭酸水素ナトリウム共沈物、合成ケイ酸アルミニウム、ステアリン酸アルミニウム、アルミニウムアラントイネート、合成ハイドロタルサイト、水酸化アルミナ・マグネシウム、水酸化アルミニウム、酢酸アルミニウム、ジヒドロキシアルミニウムアミノアセテート、カオリン、合成ヒドロタルサイト、メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウムなどが挙げられる。
【0041】
成分Cは、水溶性のものであっても、難溶性のものであってもよく、1種単独で用いても、2種以上を組み合わせて用いてもよい。なお、粘着剤組成物中の水の量が少ない場合は、メタケイ酸アルミン酸マグネシウムが好ましく、水の量が多い場合は、水酸化アルミニウムまたはジヒドロキシアルミニウムアミノアセテートが好ましい。
【0042】
成分Cは、親水性粘着剤組成物の全量に対して0.01〜20質量%の範囲、好ましくは0.1〜10質量%の範囲で添加される。成分Cの添加量が0.01質量%未満の場合には、架橋が不十分となって基剤に糸曳きが生じることがあり、20質量%を超えるとゲルが硬くなりすぎて、粘着剤組成物の粘着性が劣ってくることがある。なお、成分Cの含有量を変化させることにより、粘着性をコントロールすることができる。
【0043】
本発明の親水性粘着剤組成物には、成分C以外の架橋剤を添加してもよい。このような架橋剤としては、たとえば、
カルシウム、錫、鉄、マグネシウム、マンガン、亜鉛、バリウムなどの無機酸塩(具体的には、塩化カルシウム、塩化マグネシウム、鉄ミョウバン、硫酸第2鉄、硫酸マグネシウム、EDTA−カルシウム、EDTA−マグネシウム、塩化第1錫、炭酸カルシウム、リン酸カルシウム、リン酸水素カルシウム、炭酸マグネシウム、硫酸バリウム、ケイ酸マグネシウム、ステアリン酸マグネシウム、クエン酸マグネシウム)、水酸化物(具体的には、水酸化カルシウム、水酸化バリウム、水酸化マグネシウム、水酸化第2鉄、水酸化第1錫)および酸化物(具体的には、酸化マグネシウム);
エチレングリコールジグリシジルエーテル、グリセリンジグリシジルエーテル、ポリエチレングリコールジグリシジルエーテル、プロピレングリコールジグリシジルエーテル、ポリプロピレングリコールジグリシジルエーテルなどのエポキシ化合物;および
ホルムアルデヒド、グルタルアルデヒドなどのアルデヒド類等が挙げられる。これらの架橋剤は、1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。
【0044】
上記架橋剤は、親水性粘着剤組成物の全量に対して0.01〜5質量%の範囲、好ましくは0.1〜2質量%の範囲で添加される。上記架橋剤の添加量が0.01質量%未満の場合、架橋反応が進まずゾル状態のままとなることがあり、5質量%を超えると、架橋反応が進みすぎてゲルが硬くなり、粘着性がでなくなることがある。
【0045】
本発明の親水性粘着剤組成物は、さらに水を含んでいてもよい。水は、環状アミドモノマー/(メタ)アクリル酸系重合体とアルミニウム化合物との架橋反応を早くすることに有効である。
【0046】
水は、親水性粘着剤組成物の全量に対して40質量%以下で添加されることが好ましい。水の添加量が40質量%を超えると、粘着剤組成物中での薬効成分の溶解性が悪くなり、またその拡散速度も低下し、皮膚への吸収性が低下することがある。
【0047】
水を添加する場合、水酸化ナトリウムなどのアルカリ性物質を、(メタ)アクリル酸成分の中和剤として併用することが好ましい。アルカリ性物質の添加により、環状アミドモノマー/(メタ)アクリル酸系重合体とアルミニウム化合物との架橋反応がさらに良好に進行し、また環状アミドモノマー/(メタ)アクリル酸系重合体の溶解性および増粘性の向上にも寄与する。
【0048】
本発明に用いることができるアルカリ性物質としては、たとえば、アルカリ金属水酸化物、アルカリ土類金属水酸化物、第1級、第2級もしくは第3級のアルキルアミン、または第1級、第2級もしくは第3級のアルカノールアミンなどが挙げられ、
具体的には、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウム、アンモニア、アンモニア水、トリエタノールアミン、ジメチルアミン、ジエチルアミン、トリメチルアミン、トリエチルアミン、トリイソプロパノールアミン、リン酸三ナトリウム、リン酸水素二ナトリウム、リン酸水素二カリウム、モノエタノールアミン、ジエタノールアミン、ジイソプロパノールアミン、ポリエタノールアミンなどが挙げられる。これらの中では、水酸化ナトリウム、アンモニア水、トリエタノールアミン、ジイソプロパノールアミンが皮膚への刺激性の面から好ましい。
【0049】
上記アルカリ性物質は、親水性粘着剤組成物の全量に対して0.01〜20質量%の範囲、好ましくは0.05〜10質量%の範囲で添加される。
【0050】
本発明の親水性粘着剤組成物には、さらに架橋反応の速度調整剤として、酸を添加することが好ましい。本発明で用いられる酸としては、たとえば、酒石酸、クエン酸、乳酸、グリコール酸、リンゴ酸、サリチル酸、フマール酸、メタンスルホン酸、マレイン酸、酢酸などの有機酸、EDTA−2ナトリウム、尿素、トリエチルアミン、アンモニアなどの金属イオンに対してキレートもしくは配位能をもつ有機酸、これらの有機酸塩などの他に、塩酸、リン酸、硫酸、硝酸、臭化水素酸などの無機酸等が挙げられる。これらの中では、有機酸が好ましく、特に一分子中に水酸基およびカルボキシル基の両方を有する酒石酸、クエン酸、乳酸、グリコール酸、リンゴ酸、グルコン酸などのオキシカルボン酸が好ましい。
【0051】
上記酸は、親水性粘着剤組成物の全量に対して5質量%以下で添加されることが好ましい。
【0052】
本発明の親水性粘着剤組成物には、粘着層の保型性向上を目的として他の高分子化合物を添加してもよい。このような高分子化合物としては、ポリビニルピロリドン、架橋型ポリアクリル酸であるカルボキシビニルポリマー、ビニルピロリドン−アクリル酸エチル共重合体、N−ビニルアセトアミド−アクリル酸ナトリウム共重合体などのN−ビニルアセトアミド系共重合体、N−ビニルアセトアミド単独重合体、ポリビニルスルホン酸、N−ビニルアセトアミド架橋物、ポリイタコン酸、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロースなどが挙げられる。
【0053】
上記高分子化合物は、親水性粘着剤組成物の全量に対して0.1〜20質量%の範囲、好ましくは1〜10質量%の範囲で添加される。高分子化合物の添加量が0.1質量%未満の場合には保型性が十分に出ず、20質量%を超えると粘着層が硬くなり、皮膚との密着感が悪化し、結果として薬効成分の吸収性が劣ることがある。
【0054】
本発明の親水性粘着剤組成物を用いて投与することのできる薬効成分(成分D)としては、特に限定されないが、たとえば以下のものが挙げられる。
(a)コルチコステロイド類:具体的には、ハイドロコーチゾン、プレドニゾン、ベクロメタゾンピロピオネート、フルメタゾン、トリアムシノロン、トリアムシノロンアセトニド、フルオシノロン、フルオシノロンアセトニド、フルオシノロンアセトニドアセテート、プロピオン酸クロベタゾール等。
(b)消炎鎮痛剤:具体的には、サリチル酸、サリチル酸グリコール、サリチル酸メチル、1−メントール、カンファー、スリンダック、トリメチンナトリウム、ナプロキセン、フェンブフェン、ピロキシカム、トリアムシノロン、酢酸ヒドロコルチゾン、インドメタシン、ケトプロフェン、アセトアミノフェン、メフェナム酸、フルフェナム酸、イブフェナック、ロキソプロフェン、チアプロフェン、プラノプロフェン、フェンプフェン、ジクロフェナック、ジクロフェナクナトリウム、アルクロフェナック、ロルノキシカム、メプラノプロフェン、オキシフェンブタゾン、イブプロフェン、フェルピナク、ケトロナック、ベルモプロフェン、ナプメトン、ナプロキセン、フルルビプロフェン、フルオシノニド、プロピオン酸クロベタゾール、COX−2阻害剤(ニメスリド、メロキシカムなど)等。
(c)抗真菌剤:具体的には、クロトリマゾール、トルナフテート、硝酸エコナゾール、硝酸オモコナゾール、硝酸チオコナゾール、硝酸ケトコナゾール、硝酸ミコナゾール、硝酸イソコナゾール、トルナフテート、硝酸チオコナゾール、硝酸スルコナゾール、ピロールニトリン、ビマフシン、ウンデシレン酸、サリチル酸、シッカニン、ナイスタチン、ノルナフテート、エキサラミド、フェニルヨードウンデシノエーハ、チアントール、シクロピロクスオラミン、ハロプロジン、トリコマイシン、バリオチン、ペンタマイシン、アムホテリシンB等。
(d)抗ヒスタミン剤:具体的には、塩酸テトラサイクリン、塩酸ジフェンヒドラミン、クロルフェニラミン、ジフェニルイミダゾール、クロラムフェニコールなどの抗生物質、ジフェンヒドラミン、マレイン酸クロルフェニラミン等。
(e)催眠鎮静剤:具体的には、フェノバルビタール、アモバルビタール、シクロバルビタール、ロラゼパム、ハロペリドール等。
(f)精神安定剤:具体的には、フルフェナジン、テオリダジン、ジアゼパム、フルニトアゼパム、クロルプロマジン等。
(g)抗高血圧剤:具体的には、クロニジン、塩酸クリニジン、ピンドロール、プロプラノール、塩酸プロプラノール、ブフラノール、インデノロール、ブクモロール、ニフェジピン等。
(h)降圧利尿剤:具体的には、ハイドロサイアザイド、ベンドロフルサイアザイド、シクロペンチアザイド等。
(i)抗生物質:具体的には、ペニシリン、テトラサイクリン、オキシテトラサイクリン、硫酸フラジオマイシン、エリスロマイシン、クロラムフェニコール等。
(j)麻酔剤:具体的には、リドカイン、ベンゾカイン、アミノ安息香酸エチル、ジブカイン等。
(k)抗菌性物質:具体的には、塩化ベンザルコニウム、ニトロフラゾン、ナイスタチン、アセトスルフアミン、クロトリマゾール等。
(l)ビタミン剤:具体的には、ビタミンA、エルゴカルシフェロール、コレカルシフェロール、オクトチアシン、リボフラビン酪酸エステル等。
(m)抗てんかん剤:具体的には、ニトロゼパム、メプロパメート、クロナゼパム等。
(n)冠血管拡張剤:具体的には、ツロブテロール、ニトログリセリン、ニトログリコール、イソソルビジナイトレート、エリスルトールテトラナイトレート、ペンタエリスリトールテトラナイトレート、プロパチルナイトレート等。
(o)抗ヒスタミン剤:具体的には、塩酸ジフェンヒドラミン、クロルフェニラミン、ジフェニルイミダゾール等。
(p)鎮咳剤:具体的には、デキストロメトルファン、テルブタミン、エフェドリン、塩酸エフェドリン等。
(q)性ホルモン:具体的には、プロゲステロン、エストラジオール等。
(r)抗うつ剤:具体的には、ドキセピン等。
(s)狭心症治療剤:具体的には、ジエチルアミド、カンフルなどの制汗剤、ニトログリセリン、硝酸イソソルビド等。
(t)麻薬性鎮痛剤:具体的には、塩酸モルヒネ、塩酸エチルモルヒネ、硫酸モルヒネ、塩酸コカイン、塩酸ペチジン、リン酸コデイン、リン酸ジヒドロコデイン、クエン酸フェンタニール、スフェンタニール、塩酸メペリジン等。
(u)生薬:具体的には、オウバク、オイヒ、オンジ、ガジュツ、カミツレ、カロニン、カンゾウ、キキョウ、キョウニン、ゴオウ、ゴミシ、サイカチ、サイコ、サイシン、シヤゼンシ、ショウマ、セネガ、ソウジュツ、ソウハクヒ、チョウジ、チンピ、トコン、ナンテンジツ、バイモ、バクモンドウ、ハンゲ、ビヤクジュツ、ヒヨス、ボウホウ、マオウ等。
(v)その他:オキシブチニン、5−フルオロウラシル、ジヒドロエルゴタミン、フェンタニール、デスモプレシン、ジゴキシン、メトクロプラシド、ドンペリド、スコポラミン、臭化水素酸スコポラミン等の他に、動物用医薬品、睡眠薬、循環器系治療薬、脳代謝賦活薬、殺菌剤、酵素製剤、酵素阻害剤、生体医薬(ポリペプチド)、角化症治療剤、麻薬、抗悪性腫瘍剤、全身麻酔剤、抗不安剤、喘息・鼻アレルギー剤、抗パーキンソン剤、化学療法剤、駆虫剤、抗原虫剤、止血剤、強心剤、興奮剤・覚醒剤、習慣性中毒用剤、漢方剤、放射性医薬品、泌尿生殖器、肛門用剤、血糖降下剤、抗潰瘍剤、頭髪用剤、金属イオン封鎖剤、発汗防止剤、トランキライザー、抗擬血剤、抗リュウマチ、抗痛風剤および抗凝固薬等を挙げることができる。これらの薬効成分は、1種単独で用いてもよく、2種類以上を組み合わせて用いてもよい。
【0055】
上記薬効成分は、親水性粘着剤組成物の全量に対して0.01〜30質量%の範囲、好ましくは2〜20質量%の範囲で配合されることが望ましい。
【0056】
上記薬効成分は、溶液段階(もしくはゲル懸濁段階)または架橋反応のための熟成後に、内含させることができる。内含させる方法は、その薬効成分の物性、投与部位および放出速度に対する初期の目的に応じて適宜行えばよい。
【0057】
本発明の親水性粘着剤組成物には、これら薬効成分の吸収を促進する補助剤を添加してもよい。本発明で用いることができる補助剤としては、たとえば、
エチルアルコール、イソプロピルアルコール、ブタノール、ポリエチレングリコール#400、ベンジルアルコール、フェニルエチルアルコール、ヘキシルドデカノール、プロパノールなどのアルコール類;
オレイルアルコール、ステアリルアルコール、ラウリルアルコールなどの高級アルコール類;
尿素、イオウなどの角質軟化剤;
ピロリドンカルボン酸などの保湿剤;
プロピレングリコールモノオレート、ポリオキシエチレンソルビタンモノステアレート、ソルビタンモノステアレート、グリセリンモノステアレートなどの界面活性剤;
ミリスチン酸イソプロピル、セバシン酸ジエチルなどのエステル類;
ステアリン酸、ヘキサン酸、ノナン酸、デカン酸、ドデカン酸、テトラデカン酸、ヘキサデカン酸、オクタデカン酸、オレイン酸、リノール酸などの脂肪酸;
メントール、メントン、リモネン、ピネン、ピペリトン、テルピネン、テルピノレン、テルピノロール、カルペオールなどのテルペン系化合物;
アラントイン、ジイソプロピルアジペート、ジエチルセバケート、エチルラウレート、ラノリン、エイゾンなどの助剤;
メントール、カンフルなどの清涼化剤;
アーモンド油、オリーブ油、ツバキ油、パーシック油、ハッカ油、ゴマ油、ダイズ油、ミンク油、綿実油、トウモロコシ油、サフラワー油、ヤシ油、ユーカリ油、ヒマシ油、流動パラフィン、ワセリン、スクワレン、スクワラン、ラノリンなどの油成分;
カルボキシビニルポリマーなどのゲル化剤;
ジイソプロパノールアミンなどの中和剤;および
その他の化合物として、クロタミトン、炭酸プロピレン、1−ゲラニルアザシルクロヘプタン−2−オン(GACH)、脂肪酸ジアルキロールアミド、サリチル酸、サリチル酸誘導体等が挙げられる。
【0058】
上記補助剤は、1種単独で、または2種以上を組み合わせて配合することができるが、皮膚刺激性などを考慮すると、補助剤の配合量は、親水性粘着剤組成物100質量部に対して0.1〜5質量部であることが望ましい。
【0059】
本発明の粘着剤組成物には、その特性をより多く発現させるため、あるいは加工・成形性および品質の向上、粘着剤組成物中の薬効成分の分散性および安定性の向上などの目的に応じて、下記の添加剤を粘着剤の性能を損なわない程度に、任意に配合することができる。
(1)湿潤剤:たとえば、dl−ピロリドンカルボン酸、乳酸ナトリウム等。
(2)収れん剤:たとえば、塩化アルミニウム、硫酸アルミニウム、アラントインクロルヒドロキシアルミニウム、アラントインジヒドロキシアルミニウム、アルミニウムフェノールスルホン酸、パラフェノールスルホン酸亜鉛、硫酸亜鉛、アルミニウムクロロヒドロオキシド等。
(3)保湿剤:たとえば、乳酸ナトリウムなどのNMF成分、ヒアルロン酸、コラーゲン、ムコ多糖類、コンドロイチン硫酸などの水溶性高分子等。
(4)増粘剤:たとえば、アラビアガム、トラガントガム、ローカストビーンガム、グアーガム、エコーガム、カラヤガム、寒天、デンプン、カラゲナン、アルギン酸、アルギン酸塩(具体的には、アルギン酸ナトリウム)、アルギン酸プロピレングリコール、デキストラン、デキストリン、アミロース、ゼラチン、コラーゲン、プルラン、ペクチン、アミロペクチン、スターチ、アミロペクチンセミグリコール酸ナトリウム、キチン、アルブミン、カゼインなどの天然の高分子化合物;
ポリグルタミン酸、ポリアスパラギン酸、メチルセルロース、エチルセルロース、プロピルセルロース、エチルメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルスターチ、アルカリ金属カルボキシメチルセルロース、アルカリ金属セルロース硫酸塩、セルロースグラフト重合体、架橋ゼラチン、セルロースアセテートフタレート、デンプン−アクリル酸グラフト重合、無水フタル酸変性ゼラチン、コハク酸変性ゼラチンなどの半合成の高分子化合物;
ポリビニルアルコール、ポリビニルピロリドン、ビニルメチルエーテル/無水マレイン酸共重合体、カルボキシビニルポリマー、ビニルピロリドン−アクリル酸エチル共重合体、ビニルピロリドン−スチレン共重合体、ビニルピロリドン−酢酸ビニル共重合体、ビニルアセテート−(メタ)アクリル酸共重合体、ポリビニルアセテート−クロトン酸共重合体、N−ビニルアセトアミド−アクリル酸ナトリウム共重合体などのN−ビニルアセトアミド系共重合体、ポリビニルスルホン酸、N−ビニルアセトアミド架橋物、ポリイタコン酸、ポリヒドロキシエチルアクリレート、ポリアクリルアミド、スチレン−マレイン酸無水物共重合体、アクリルアミド−アクリル酸共重合体、酢酸ビニル−(メタ)アクリル酸共重合体、酢酸ビニル−クロトン酸共重合体などの合成の高分子化合物等。
(5)粘着付与物質:たとえば、シリコーンゴム、ポリイソブレンゴン、スチレン−ブロック共重合体ゴム、アクリルゴム、天然ゴムなどの各粘着性物質等。
(6)止痒剤:たとえば、カンフル、チモール、メントール、ポリオキシエチレンラウリルエーテル、抗ヒスタミン剤、アミノ安息香酸エチル等。
(7)角質軟化剥離剤:たとえば、イオウ、チオキソロン、硫化セレン、サリチル酸、レゾルシン等。
(8)誤食防止物質:たとえば、唐辛子粉、トウガラシエッセンス等。
(9)粉体原料:たとえば、モンモリロラート、無水ケイ酸、石コウ、カーボンブラック、珪藻土、ベンガラ、炭酸カルシウム、ヒドロタルサイト、タルク、ガラス、カオリン、ベントナイト、金属石鹸、エーロジル、雲母チタン、オキシ塩化ビスマス、魚鱗箔等、亜鉛華、二酸化チタン等。
(10)油性原料:たとえば、アーモンド油、オリーブ油、硬化油、つばき油、ヒマシ油、モクロウ油、ヤシ油、ミツロウ、鯨ロウ、ラノリン、カルナバロウ、キャンデリラロウ、流動パラフィン、ワセリン、マイクロクリスタリンワックス、セレシン、スクワレン、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、イソステアリン酸、オレイン酸、ラウリルアルコール、セタノール、ステアリルアルコール、オレイルアルコール、オクチルドデカノール、コレステロール、ヘキシルデカノール、ワイトステロール、乳酸セチル、ミリスチン酸イソプロピル、ラウリン酸ヘキシル、ミリスチン酸ミリスチル、パルミチン酸イソプロピル、ミリスチン酸オクチルドデカノール、ステアリン酸ブチル、カカオ油、木ロウ、ホホバ油、グレープシード油、アボカド油、ミンク油、卵黄油、蜜ロウ、鯨ロウ、ラノリン、カルナウバロウ、キャンデリラロウ、流動パラフィン、セレシンワックス、パラフィンワックス、ベヘニン酸、アジピン酸イソプロピル、ミリスチン酸オクチルドデシル、オレイン酸オクチルドデシル、コレステロールオレエート等。
(11)界面活性剤:たとえば、ラウリル硫酸エステル塩、ポリオキシエチレンアルキルエーテル硫酸塩、アルキルベンゼンスルホン酸塩、ポリオキシエチレンアルキルエーテルリン酸、ポリオキシエチレンアルキルフェニルエーテルリン酸、N−アシルアミノ酸塩、ステアリン酸ナトリウム、パルミチン酸カリウム、セチル硫酸ナトリウム、ラウリル硫酸ナトリウム、パルミチン酸トリエタノールアミン、ポリオキシエチレンラウリルリン酸ナトリウム、アシルグルタミン酸ナトリウム、サーファクチンなどのアニオン界面活性剤;
塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ステアリルトリメチルアンモニウム、塩化ジステアリルジメチルアンモニウム、塩化ステアリルジメチルベンジルアンモニウムなどのカチオン界面活性剤;
塩酸アルキルジアミノエチルグリシン、2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン、ラウリルジメチルアミノ酢酸ベタイン、レシチンなどの両性界面活性剤;
ポリオール脂肪酸エステル、モノステアリン酸グリセリン、親油型モノオレイン酸グリセリン、モノステアリン酸エチレングリコール、モノステアリン酸プロピレングリコール、ソルビタン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンアルキルフェノールエーテル、ポリオキシエチレンソルビトール脂肪酸エステル、N−アシルアミノ酸エステル、ショ糖脂肪酸エステル、脂肪酸アルキロールアミド、ポリオキシエチレン化ステロール、ポリオキシエチレン化ラノリン、ポリオキシエチレン硬化ヒマシ油などの非イオン性界面活性剤等。
(12)着色剤:たとえば、黄酸化鉄、ベンガラ、黒酸化鉄、群青、カーボンブラック、水酸化クロム、酸化クロム、タール色素、レーキ、赤色2号、赤色3号、赤色102号、赤色201号、黄色4号、黄色5号、青色1号、青色2号等。
(13)香料:たとえば、芥子油、オレンジ油、胡椒油、ジャスミン油、杉油、ショウブ油、テルピン油、橙花油、バラ油、ユーカリ油、ライム油、レモン油、和種ハッカ油、ローズマリー油などの植物性香料;ムスク、レイビョウコウ、カイリコウ、リュウゼンコウなどの動物性香料;ブロモスチロール、ピネン、リモネンなどの炭化水素系香料;ベンジルアルコール、l−メントールなどのアルコール系香料;酢酸エチル、サリチル酸メチルなどのエステル類系香料;ベンズアルデヒド、サリチルアルデヒドなどのアルデヒド類系香料;カンファー、ムスコン、ムスクケトン、l−メントンなどのケトン類系香料サフロールなどのエーテル類系香料;チモールなどのフェノール類系香料;ラクトン類系香料;フェニル酢酸などの酸系香料;インドールなどの窒素化合物系香料等。
(14)紫外線遮断剤:たとえばASL−24TM、Cyasorb UV−9TM、Uvinul M−40TMなどのベンゾフェノン系;SalolTMなどの安息香酸系、Tinuvin PTMなどのアゾール系;Uvinul N−35TMなどのニトリル系;Ancour UATMなどの尿素系;Neo Heliopan Give tan FTM、2−ヒドロキシ−4−メトキシベンゾフェノン、オクチルジメチルパラアミノベンゾエート、エチルヘキシルパラメトキシサイナメートなどのパラアミノ酸系、サリチル酸系、ベンゾフラン系、クマリン系、アゾール系等。
(15)防腐殺菌剤:たとえば、安息香酸、サリチル酸、デヒドロ酢酸、ソルビン酸、アクリル酸、メタクリル酸などの有機酸;パラオキシ安息香酸エステル、フェノキシエタノール、チモール、ヒノキチオール、チオキソロンなどのフェノール類;ヘキサクロロフェン、2,4,4’−トリクロロ−2’−ヒドロキシジフェニルエーテルなどのハロゲン化ビスフェノール類;トリクロロカルバニリド、ハロカルバン、ウデシレン酸モノエタノールアミドなどのアミド化合物類;塩化ベンザルコニウム、臭化アルキルイソキノリニウム、塩化ベンゼトニウム、塩化セチルピリジニウムなどの4級アンモニム化合物類;ラウリルジ(アミノエチル)グリシンなどの両性界面活性剤;2−ピリジンチオール−1−オキシド亜鉛塩、グルコン酸、クロルヘキシジン、チラム、N−トリクロロメチルチオ−4−シクロヘキセン−1.2−ジカルボキシイミド、クロロブタノール等。
(16)酸化防止剤:たとえば、ノルジヒドログアヤレチン酸、グアヤク脂、没食子酸プロピル、ブチルヒドロキシアニソール、ジブチルヒドロキシトルエン(BHT)、トコフェロール(ビタミンE)、2,2’−メチレンビス(4−メチル−6−t−ブチル)フェノール等。
(17)キレート剤:たとえば、エデト酸塩、ピロリン酸塩、ヘキサメタリン酸塩等。
(18)紫外線散乱剤:たとえば、酸化チタン、カオリン、タルク等。
【0060】
上記以外にも、安定剤、充填剤、保存剤、可塑剤、軟化剤、劣化防止剤などを添加してもよく、これら添加剤は得られる親水性粘着剤組成物の特性に影響を与えない範囲で任意に加えることができる。
【0061】
本発明の親水性粘着剤組成物には、上述したように、酸およびアルカリ性物質を使用することができるが、皮膚への刺激低減などのために最終的な粘着剤組成物のpHを調整する必要がある。
【0062】
本発明で用いることができるpH調整剤としては、特に制限はなく、たとえば、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウム、アンモア、アンモニア水、トリエタノールアミン、ジメチルアミン、ジエチルアミン、トリメチルアミン、トリエチルアミン、トリイソプロパノールアミン、リン酸三ナトリウム、リン酸水素二ナトリウム、リン酸水素二カリウム、モノエタノールアミン、ジエタノールアミン、ジイソプロパノールアミン、ポリエタノールアミンなどのアルカリ金属水酸化物、アルカリ土類金属水酸化物、第1級、第2級もしくは第3級のアルキルアミン、または第1級、第2級もしくは第3級のアルカノールアミンなどのアルカリ、あるいは、クエン酸、酒石酸、乳酸、グリコール酸、塩酸、硝酸、リンゴ酸、リン酸などの酸が挙げられる。
【0063】
また、酸性またはアルカリ性を示す高分子化合物を用いることもでき、たとえば、アルギン酸、ポリグルタミン酸、ポリアスパラギン酸、デンプン−アクリル酸グラフト重合体、ポリアクリル酸、ポリビニルアセテート−クロトン酸共重合体、酢酸ビニル−(メタ)アクリル酸共重合体、酢酸ビニル−クロトン酸共重合体、ポリビニルスルホン酸、ポリイタコン酸、スチレン−マレイン酸無水物共重合体、アクリルアミド−アクリル酸共重合体などが挙げられる。
【0064】
本発明の親水性粘着剤組成物は優れた性質を有しているので、下記のような種々の用途に応用することができる。
(i)医薬品:たとえば、経皮吸収用製剤、経粘膜吸収用製剤などの貼付剤等。
(ii)化粧品、医薬部外品:たとえば、パック剤、ニキビ用品等。
【0065】
上記のような用途に用いるために、本発明の親水性粘着剤組成物は、直接、各種原料を混合後、ゾル状態で適当な型に流し込み、そこで架橋させて成形されるか、架橋後のゲルを適当な成形機、打錠機などを用いて各種成形物に調製される。
【0066】
原料の混合は、たとえば、ニーダー、コニーダー、ニーダールーダー、アジホモミキサー、プラネタリーミキサー、ダブルプラネタリーミキサーなどを適宜選択して使用することにより行うことができる。
【0067】
本発明の親水性粘着剤組成物をシート化するには、紙、木材、金属、ガラス繊維、布(ネル、織布、不織布等)、合成樹脂(ポリウレタン、エチレン酢酸ビニル共重合体、ポリ塩化ビニル、ポリエステル、ポリオレフィン、ポリアミド、ポリ塩化ビニリデン、ポリテトラフルオロエチレン等)、アルミニウムなどの金属箔、ゴムまたはセルロース誘導体およびこれらとプラスチックフィルムとの積層フィルムなどの成形品、シート(箔)、またはテープなどの支持体の1面あるいは両面に親水性粘着剤を適量塗布すればよい。
【0068】
得られたシート状の親水性粘着剤の保存を容易にするためには、親水性粘着剤を塗布した面に、シリコンまたはその他の適当な方法で処理した剥離シートを貼着しておくか、あるいは親水性粘着剤を塗布していない面をシリコンまたはその他の適当な方法で処理して剥離面とし、親水性粘着剤を塗布した面と親水性粘着剤が塗布されていない剥離面とが重なるように巻いておく、または重ねておくことが望ましい。なお、剥離シートとしては、ポリエチレンフィルム、ポリプロピレンフィルム、剥離紙、セロハン、ポリ塩化ビニル、ポリエステルなどが用いられる。
【0069】
【発明の効果】
本発明の親水性粘着剤組成物は、環状アミドモノマー/(メタ)アクリル酸共重合体および薬効成分を高濃度の多価アルコールに分散もしくは溶解してなるもので、粘着層の骨格間に多量の多価アルコールを含有することができ、それらが離しょうすることのない安定した粘着層を形成することができる。また、親水性粘着剤組成物を用いた貼付剤は、放出特性および粘着性に優れ、かつ高い安全性を有する。
【0070】
【実施例】
以下、実施例に基づいて本発明をさらに具体的に説明するが、本発明はこれら実施例に限定されるものではない。なお、本実施例における「部」とは質量部を意味する。
<N−ビニル−ピロリドン/アクリル酸共重合体の製造例>
3ツ口セパラブルフラスコに撹拌機および冷却管を装着し、これに、N−ビニルピロリドン42g、アクリル酸18gおよび酢酸エチル540gを仕込んだ。さらに、ジメチル2,2’−アゾビス(2−メチルプロピオネート)0.3gを添加し、酢酸エチルの沸点まで加熱した。重合が進むにつれて、均一溶液から沈殿が析出した。5時間重合反応を行い、冷却後、濾過した。得られた沈殿物を真空乾燥して解砕することにより、微粉状のN−ビニルピロリドン/アクリル酸共重合体を得た。
【0071】
上記のようにして得られた共重合体をイソプロパノール/水=1/1(容量比)混合液に溶解して10質量%の溶液とし、この溶液に10質量%の水酸化ナトリウム溶液を添加して、共重合体のアクリル酸部分を中和した溶液の粘度は200mPa・s(25℃)であった。
【0072】
【実施例1】
(配合)
N−ビニル−ピロリドン/アクリル酸共重合体(80/20重量比) 10部
グリセリン 88部
メタケイ酸アルミン酸マグネシウム 1部
ツロブテロール 1部
(処方)
グリセリン70部およびメタケイ酸マグネシウム1部からなる混合液に、N−ビニルピロリドン/アクリル酸共重合体(80/20重量比)10部を徐々に加えながら溶解させた後、グリセリン18部およびツロブテロール1部からなる混合液をゆっくりと加えながら、均一になるまで混合した。
【0073】
得られたゾルを成形して密封し、約20℃で3日間熟成して得られたゲルは、伸縮性および強い反発力を有していた。
【0074】
【実施例2】
(配合)
N−ビニル−3−メチルピロリドン/メタクリル酸共重合体
(50/50重量比) 3部
N−メチル−2−ピロリドン 7部
プロピレングリコール 79.5部
ケイ酸アルミン酸マグネシウム 0.5部
N−ビニルアセトアミド・アクリル酸ナトリウム共重合体
(90/10重量比) 5部
オキシブチニン 5部
(処方)
プロピレングリコール79.5部およびケイ酸アルミン酸マグネシウム0.5部からなる混合液に、N−ビニル−3−メチルピロリドン/メタクリル酸共重合体(50/50重量比)3部およびN−ビニルアセトアミド・アクリル酸ナトリウム共重合体(90/10重量比)5部を徐々に加えながら溶解させた後、N−メチル−2−ピロリドン7部およびオキシブチニン5部からなる混合液をゆっくりと加えながら、均一になるまで混合した。
【0075】
得られたゾルを成形して密封し、約20℃で3日間熟成して得られたゲルは、伸縮性および強い反発力を有していた。
【0076】
【実施例3】
(配合)
N−ビニル−5−メチルピロリドン/アクリル酸共重合体
(20/80重量比) 5部
グリセリン 30部
1,3−ブチレングリコール 19.2部
精製水 40部
カルボキシビニルポリマー 2部
乾燥水酸化アルミニウムゲル 0.4部
酒石酸 0.6部
水酸化ナトリウム 1.8部
ジクロフェナクナトリウム 1部
(処方)
水酸化ナトリウム1.8部および精製水20部からなる溶液に、N−ビニル−5−メチルピロリドン/アクリル酸共重合体(20/80重量比)5部およびグリセリン30部からなる混合液を加え、均一になるまで練合した。次いで、1,3−ブチレングリコール19.2部、カルボキシビニルポリマー(カーボポール934:NOVEON社)2部、ジクロフェナクナトリウム1部および乾燥水酸化アルミニウムゲル(協和化学工業(株)製)0.4部からなる混合液を徐々に加えながら、均一になるまで練合し、さらに、酒石酸0.6部および精製水20部からなる溶液を一度に加えて練合した。
【0077】
得られたゾルを成形して密封し、約20℃で3日間熟成して得られたゲルは、伸縮性および強い反発力を有していた。
【0078】
【実施例4】
(配合)
N−ビニル−カプロラクタム/アクリル酸共重合体
(40/60重量比) 8部
ヒドロキシプロピルセルロース 3部
乳酸 1部
ジヒドロキシアルミニウムアミノアセテート 1部
トリエチレングリコール 55.5部
N−ビニルアセトアミド架橋物 2部
精製水 30部
N−エチル−2−ピロリドン 10部
ジイソプロパノールアミン 0.5部
インドメタシン 1部
(処方)
ジイソプロパノールアミン0.5部および精製水20部からなる溶液に、N−ビニル−カプロラクタム/アクリル酸共重合体(40/60重量比)8部、ジヒドロキシアルミニウムアミノアセテート1部およびトリエチレングリコール55.5部からなる混合液を加えて、均一になるまで練合した。次いで、N−エチル−2−ピロリドン10部、N−ビニルアセトアミド架橋物2部およびインドメタシン1部からなる混合液を徐々に加えて練合し、さらに、乳酸1部および精製水10部からなる溶液を加えて、均一になるまで練合した。
【0079】
得られたゾルを成形して密封し、約20℃で3日間熟成して得られたゲルは、伸縮性および強い反発力を有していた。
【0080】
[参考例]
(配合)
N−ビニル−3−メチルピロリドン/メタクリル酸共重合体
(95/5重量比) 3部
N−メチル−2−ピロリドン 7部
プロピレングリコール 79.5部
ケイ酸アルミン酸マグネシウム 0.5部
N−ビニルアセトアミド・アクリル酸ナトリウム共重合体
(90/10 重量比) 5部
オキシブチニン 5部
(処方)
プロピレングリコール79.5部およびケイ酸アルミン酸マグネシウム0.5部からなる混合液に、N−ビニル−3−メチルピロリドン/メタクリル酸共重合体(95/5重量比)3部およびN−ビニルアセトアミド・アクリル酸ナトリウム共重合体(90/10重量比)5部を徐々に加えながら溶解させた。次いで、N−メチル−2−ピロリドン7部およびオキシブチニン5部からなる混合液をゆっくりと加えながら、均一になるまで混合した。
【0081】
得られたゾルを成形して密封し、約20℃で3日間熟成して得られたゲルは、反発力が若干弱く、触るとゲルから液が若干しみ出してきた。
【0082】
【比較例1】
(配合)
ポリアクリル酸 10部
グリセリン 88部
メタケイ酸アルミン酸マグネシウム 1部
ツロブテロール 1部
(処方)
グリセリン70部およびメタケイ酸マグネシウム1部からなる混合液に、ポリアクリル酸(10部)を徐々に加えながら溶解させた。次いで、グリセリン18部およびツロブテロール1部からなる混合液をゆっくりと加えながら、均一になるまで混合した。
【0083】
得られたゾルを成形して密封し、約20℃で3日間熟成して得られたゲルは、全く反発力はなく、触るとグリセリンがしみ出し、ゾルが指に付着した。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a hydrophilic pressure-sensitive adhesive composition containing a copolymer composed of a cyclic amide monomer and (meth) acrylic acid, and more specifically, a medicinal component is dispersed or dissolved in a high-concentration polyhydric alcohol. Accordingly, the present invention relates to a hydrophilic adhesive composition for a percutaneously absorbable external preparation having excellent drug release characteristics and adhesiveness and high safety.
[0002]
[Prior art]
In recent years, it has been confirmed that alcohols such as polyhydric alcohols increase the solubility and transdermal absorbability of drugs in oral vaginal mucosa preparations and transdermal absorption preparations for medical use. It has been a subject to contain various alcohols in a patch at a high concentration.
[0003]
Generally, percutaneous absorption preparations are classified into two types, non-aqueous preparations such as plasters and tapes, and hydrous preparations such as poultices.
[0004]
Acrylic or rubber-based adhesives are used for non-aqueous preparations, but although the drug has good percutaneous absorption, it is highly irritating to the skin due to its strong adhesiveness. It has been difficult to apply to drugs that need to be applied repeatedly. In addition, since the pressure-sensitive adhesive is not hydrophilic, it is easily peeled off by sweat or body fluid, and there is a problem that a gap is formed between the skin and the preparation, resulting in a decrease in drug absorbability. Furthermore, the acrylic polymer still has the problem of toxicity of residual monomers, and skin irritation due to residual monomers may occur, particularly when applied to the skin.
[0005]
On the other hand, water-containing preparations are generally natural water-soluble polymers such as gum tragacanth, gum arabic, carrageenan, duran gum, sodium alginate, mannan, gelatin, or polyacrylic acid (salt), polymethacrylic acid (salt), polyvinyl alcohol. In addition, a synthetic polymer such as polyacrylamide is used, and a moisturizing agent such as a polyhydric alcohol is blended therein. Since these adhesive bases are hydrophilic, they are less irritating to the skin and can be said to be suitable for long-term application, but they are poorly sticky, and basically the drugs absorbed from the skin are lipophilic. Since there are many things, the drug is difficult to dissolve in this preparation with a high water content, resulting in poor absorbability. Furthermore, it has been difficult to ensure the stability of drugs over time for drugs that are easily hydrolyzed.
[0006]
In order to avoid such a problem, for example, a pressure-sensitive adhesive base material in which solid or powdered polyacrylic acid having a 10% aqueous solution viscosity of 100 to 1000 cps is dissolved in a polyhydric alcohol has been proposed (Patent Document 1). Although polyacrylic acid can be expected to be hydrophilic and less irritating, it has a low viscosity increase when dissolved in a polyhydric alcohol, and as a result, it has been difficult to increase the adhesive strength. Further, since polyacrylic acid is an anionic polymer, when the medicinal component is cationic, an ion complex is formed and the drug release property is remarkably deteriorated. Many of the drugs absorbed from the skin are cationic, which has been a major drawback.
[0007]
In addition, a device for transdermal administration characterized in that poly-N-vinylamide is contained in a drug storage layer has been proposed (Patent Document 2). However, poly-N-pyrrolidone in this device is used for a storage layer of medicinal ingredients and does not play a role as an adhesive. Therefore, since an adhesive layer further exists between the skin and the drug storage layer, it is difficult to produce the adhesive layer, and the adhesive layer affects the absorbability of the medicinal component.
[0008]
Furthermore, 2-ethylhexyl acrylate / vinylpyrrolidone copolymer solution has already been used as an adhesive for transdermal external preparations (Non-patent Document 1). However, the pressure-sensitive adhesive is irritating because it has a remarkably low affinity with water, and it is necessary to use a low-boiling solvent such as ethyl acetate in the formulation process, which is a burden on the environment. It was.
[0009]
[Patent Document 1]
JP-A-6-135828
[Patent Document 2]
Japanese translation of PCT publication No. 8-512054
[Non-Patent Document 1]
"Pharmaceutical Additives Dictionary 2000" Yakuji Nipposha, page 1
[0010]
[Problems to be solved by the invention]
An object of the present invention is to provide a hydrophilic adsorbent having good tackiness.
[0011]
In addition, the present invention has good adhesiveness to the adherend, less irritation to the skin, and does not produce a separating solution, and has a simple composition and can be easily transdermally absorbed. An object of the present invention is to provide a hydrophilic adhesive composition having a high viscosity.
[0012]
[Means for Solving the Problems]
As a result of intensive studies in view of the above circumstances, the present inventors have found that a copolymer (cyclic amide monomer / (meth) acrylic acid copolymer) containing a cyclic amide monomer unit and a (meth) acrylic acid unit. Since the structural unit has hydrophilic functional groups such as an amide group and a carboxyl group, the hydrophilicity of the adhesive layer is improved and the moisture secreted to the skin surface is absorbed. It was found that an equilibrium state was established between the water vapor and the external water vapor, and skin peeling and blurring could be prevented. In addition, since the cyclic amide monomer is nonionic, the probability of generating an ion complex by reaction with a cationic drug is reduced, and it may have excellent transdermal absorbability for a wider range of medicinal ingredients. I found out. Furthermore, it discovered that the hydrophilic adhesive composition containing the said copolymer, an aluminum compound, and a polyhydric alcohol had the outstanding adhesiveness, and completed this invention.
[0013]
That is, the present invention comprises the following items.
(1) The following general formula (I)Repeating unit represented byandThe following general formulaRepeating unit represented by (II)Consist only ofA copolymer;At least one selected from the group consisting of magnesium aluminate metasilicate, magnesium aluminate silicate, aluminum hydroxide and dihydroxyaluminum aminoacetateContains aluminum compound and polyhydric alcoholThus, the copolymerization ratio of the repeating unit represented by the formula (I) and the repeating unit represented by the formula (II) in the copolymer is 80/20 to 20/80 by weight.A hydrophilic pressure-sensitive adhesive composition characterized by that;
[0014]
[Formula 4]
[0015]
[Chemical formula 5]
[0016]
(Wherein R1Represents an optionally substituted alkylene chain having 3 to 7 carbon atoms, R2Represents a hydrogen atom or a methyl group. R in multiple repeating units1And R2May be the same or different. )
(2)underCyclic amide monomer represented by the general formula (III) and (meth) acrylic acidConsist only ofA copolymer obtained by polymerizing the monomer mixture;At least one selected from the group consisting of magnesium aluminate metasilicate, magnesium aluminate silicate, aluminum hydroxide and dihydroxyaluminum aminoacetateContains aluminum compound and polyhydric alcoholThus, the copolymerization ratio of the cyclic amide monomer and the (meth) acrylic acid in the copolymer is 80/20 to 20/80 by weight.A hydrophilic pressure-sensitive adhesive composition characterized by that;
[0017]
[Chemical 6]
[0018]
(Wherein RThreeRepresents an alkylene chain having 3 to 7 carbon atoms which may have a substituent. )
(3(1) to (1) further comprising a medicinal component2). The hydrophilic pressure-sensitive adhesive composition according to any one of the above.
(4) Further comprising water (1) to (3). The hydrophilic pressure-sensitive adhesive composition according to any one of the above.
(5) Further comprising an alkaline substance (4). The hydrophilic pressure-sensitive adhesive composition described in the above.
(6) Further comprising an acid (4) Or (5). The hydrophilic pressure-sensitive adhesive composition described in the above.
(7) Characterized in that the acid is an oxycarboxylic acid (6). The hydrophilic pressure-sensitive adhesive composition described in the above.
(8(1) to (1) further comprising an organic solvent other than polyhydric alcohol7)One ofThe hydrophilic pressure-sensitive adhesive composition described in 1.
(9) The organic solvent is alkylpyrrolidone (8). The hydrophilic pressure-sensitive adhesive composition described in the above.
(10) (1)-(9). A patch comprising the hydrophilic pressure-sensitive adhesive composition according to any one of the above.
(11) (3) ~ (9). A transdermal external preparation characterized by using the hydrophilic pressure-sensitive adhesive composition according to any one of the above.
[0019]
DETAILED DESCRIPTION OF THE INVENTION
The hydrophilic pressure-sensitive adhesive composition of the present invention comprises a cyclic amide monomer / (meth) acrylic acid copolymer (component A) containing repeating units represented by the following general formulas (I) and (II), an aluminum compound ( componentC) And polyhydric alcohol (components)B). Furthermore, it is more effective to include a medicinal component (component D).
[0020]
[Chemical 7]
[0021]
[Chemical 8]
[0022]
Where R1Represents an optionally substituted alkylene chain having 3 to 7 carbon atoms, R2Represents a hydrogen atom or a methyl group. R in multiple repeating units1And R2May be the same or different.
[0023]
Component A used in the present invention is preferably used in a range of 0.5 to 30% by mass (hereinafter simply referred to as%), more preferably 2% to 20%, based on the total amount of the hydrophilic pressure-sensitive adhesive composition. The range is good. When the content of component A is less than 0.5%, a release liquid is generated from the pressure-sensitive adhesive layer and becomes non-uniform, and when it exceeds 30%, the viscosity of the pressure-sensitive adhesive composition during molding increases. And mixing other components can be difficult.
[0024]
Component A is usually obtained by copolymerizing a cyclic amide monomer represented by the following general formula (III) and (meth) acrylic acid.
[0025]
[Chemical 9]
[0026]
Where RThreeRepresents an alkylene chain having 3 to 7 carbon atoms which may have a substituent.
Examples of the cyclic amide monomer include N-vinylpyrrolidone, N-vinyl-3-methylpyrrolidone, N-vinyl-5-methylpyrrolidone, N-vinyl-3,3,5-trimethylpyrrolidone, N-vinylpiperidone, N -Vinylcaprolactam, N-vinylcapryllactam, etc. are mentioned.
[0027]
(Meth) acrylic acid used in the present invention refers to acrylic acid or methacrylic acid.
[0028]
The cyclic amide monomer and (meth) acrylic acid may be used alone or in combination of two or more. The copolymerization ratio of the cyclic amide monomer and (meth) acrylic acid is preferably 80/20 to 20/80, more preferably 70/30 to 30/70.
[0029]
Component A used in the present invention shares other monomer components such as esters of (meth) acrylic acid to the extent that hydrophilicity is not hindered for the purpose of improving adhesiveness and containing a drug stably. It can also be polymerized. In this case, the cyclic amide monomer and the (meth) acrylic acid component are preferably contained in an amount of 80% by mass or more, more preferably 90% by mass or more of the whole monomer. Usually, it is not necessary to use other monomers.
[0030]
Component A can be produced by copolymerizing a predetermined proportion of monomers by a known method. For example, aqueous solution polymerization, reverse layer suspension polymerization, precipitation precipitation polymerization and the like can be applied. When the polymerization is complete, a viscous liquid, agar-like or powdery product is obtained. Furthermore, the viscous liquid or agar-like product can be pulverized by dehydration drying. When the component A thus obtained is added to the hydrophilic pressure-sensitive adhesive composition of the present invention, it is preferably added in the form of powder, but the polymer concentration of the viscous liquid, the addition ratio of the polyhydric alcohol (component B) Depending on the case, it can be used as a viscous liquid.
[0031]
As the component A, it is preferable that the viscosity of a 10% by mass solution of a polymer obtained by neutralizing the (meth) acrylic acid moiety of the component A with an alkali is 6 to 2000 mPa · s.
[0032]
As a specific measurement procedure of the viscosity, first, 20 g of the dried copolymer (component A) was dissolved in isopropanol / water = 1/1 (volume ratio) to 200 g, and then with a 10% by mass alkaline solution. After neutralizing the (meth) acrylic acid portion and heating the neutralized solution to 25 ° C., the viscosity is measured at a rotation speed of 20 rpm using a Brookfield viscometer.
[0033]
A polyhydric alcohol (component B) is added to the hydrophilic pressure-sensitive adhesive composition of the present invention in order to obtain shape retention and pressure-sensitive adhesive properties. Component B is also useful for the purpose of increasing the solubility and activity of the drug in the hydrophilic pressure-sensitive adhesive composition and improving the transferability to the skin.
[0034]
Component B is not particularly limited, but ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol, triethylene glycol, 1,4-butylene glycol (dihydric alcohol), glycerin, trioxyisobutane (trihydric alcohol) ), Erythritol, pentaerythritol (tetrahydric alcohol), xylit, adnit (pentahydric alcohol), allozulcit, sorbitol, sorbitol liquid, mannitol (hexahydric alcohol), polyglycerin, dipropylene glycol and the like.
[0035]
In addition, the polyhydric alcohol in this specification refers to the thing whose total molecular weight of the OH group in the molecule | numerator is 1/50 or more of the molecular weight of the whole molecule | numerator. If it is less than 1/50, the affinity with the polymer represented by formula (I) may deteriorate. Among these, glycerin is particularly preferable in view of safety and affinity with the cyclic amide monomer / (meth) acrylic acid copolymer. Component B may be used alone or in combination of two or more.
[0036]
Component B is added in a range of 20 to 99% by mass, preferably in a range of 40 to 90% by mass, based on the total amount of the hydrophilic pressure-sensitive adhesive composition. When the addition amount of component B is less than 20% by mass or more than 99% by mass, the thickening effect by component A is hardly exhibited, and sufficient shape retention of the adhesive layer is difficult to be obtained. Sometimes.
[0037]
An organic solvent other than polyhydric alcohols can be added to the hydrophilic pressure-sensitive adhesive composition of the present invention. Examples of such organic solvents include
Methanol, ethanol, propanol, benzyl alcohol, phenethyl alcohol, isopropyl alcohol, isobutyl alcohol, hexyl alcohol, 2-ethylhexanol, cyclohexanol, octyl alcohol, butanol, pentanol, alkoxyethanol (specifically, methoxyethanol, ethoxyethanol) Monohydric alcohols such as butoxyethanol);
Ketones such as acetone and methyl ethyl ketone;
Organic solvents miscible with water, such as dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, N-cyclohexyl-2-pyrrolidone, dimethyl sulfoxide; and
Organic solvents that are immiscible with water, such as ethyl acetate and crotamiton, can be mentioned. Among these, alkylpyrrolidones such as N-methyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, and N-cyclohexyl-2-pyrrolidone increase the solubility and activity of the drug, and the cyclic amide monomer / It is preferable from the aspect of affinity with the (meth) acrylic acid copolymer.
[0038]
The said organic solvent is added in 0.01-50 mass% with respect to the whole quantity of a hydrophilic adhesive composition, Preferably it is added in 0.5-30 mass%. When the amount of the organic solvent added is less than 0.01% by mass, the solubility of the drug decreases, and the drug may precipitate in the preparation. When the amount exceeds 50% by mass, the solvent oozes out. , May not be used as a drug.
[0039]
To the hydrophilic pressure-sensitive adhesive composition of the present invention, an aluminum compound (component C) is added as a crosslinking agent for the purpose of maintaining the shape retention of the gel and preventing “glue residue”.
[0040]
Component C includes, for example, aluminum chloride, potassium alum, ammonium alum, aluminum nitrate, aluminum sulfate, EDTA-aluminum, aluminum hydroxide / sodium bicarbonate coprecipitate, synthetic aluminum silicate, aluminum stearate, aluminum allantoinate And synthetic hydrotalcite, alumina hydroxide / magnesium, aluminum hydroxide, aluminum acetate, dihydroxyaluminum aminoacetate, kaolin, synthetic hydrotalcite, magnesium aluminate metasilicate, magnesium aluminate silicate and the like.
[0041]
Component C may be water-soluble or poorly soluble, and may be used alone or in combination of two or more. When the amount of water in the pressure-sensitive adhesive composition is small, magnesium aluminate metasilicate is preferable, and when the amount of water is large, aluminum hydroxide or dihydroxyaluminum aminoacetate is preferable.
[0042]
Component C is added in the range of 0.01 to 20% by mass, preferably in the range of 0.1 to 10% by mass, based on the total amount of the hydrophilic pressure-sensitive adhesive composition. When the amount of component C added is less than 0.01% by mass, crosslinking may be insufficient and stringing may occur in the base. When the amount exceeds 20% by mass, the gel becomes too hard and the pressure-sensitive adhesive The tackiness of the composition may be inferior. In addition, adhesiveness can be controlled by changing content of the component C.
[0043]
You may add crosslinking agents other than the component C to the hydrophilic adhesive composition of this invention. As such a crosslinking agent, for example,
Inorganic acid salts such as calcium, tin, iron, magnesium, manganese, zinc, barium (specifically, calcium chloride, magnesium chloride, iron alum, ferric sulfate, magnesium sulfate, EDTA-calcium, EDTA-magnesium, chloride) Stannous, calcium carbonate, calcium phosphate, calcium hydrogen phosphate, magnesium carbonate, barium sulfate, magnesium silicate, magnesium stearate, magnesium citrate), hydroxide (specifically, calcium hydroxide, barium hydroxide, Magnesium hydroxide, ferric hydroxide, stannous hydroxide) and oxides (specifically, magnesium oxide);
Epoxy compounds such as ethylene glycol diglycidyl ether, glycerin diglycidyl ether, polyethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether; and
Examples include aldehydes such as formaldehyde and glutaraldehyde. These crosslinking agents may be used alone or in combination of two or more.
[0044]
The said crosslinking agent is added in 0.01-5 mass% with respect to the whole quantity of a hydrophilic adhesive composition, Preferably it is 0.1-2 mass%. When the addition amount of the crosslinking agent is less than 0.01% by mass, the crosslinking reaction may not proceed and may remain in a sol state. When the amount exceeds 5% by mass, the crosslinking reaction proceeds excessively, the gel becomes hard, and the adhesive Sexuality may be lost.
[0045]
The hydrophilic pressure-sensitive adhesive composition of the present invention may further contain water. Water is effective for speeding up the crosslinking reaction between the cyclic amide monomer / (meth) acrylic acid polymer and the aluminum compound.
[0046]
Water is preferably added in an amount of 40% by mass or less based on the total amount of the hydrophilic pressure-sensitive adhesive composition. When the added amount of water exceeds 40% by mass, the solubility of the medicinal component in the pressure-sensitive adhesive composition is deteriorated, the diffusion rate is also lowered, and the absorbability to the skin may be lowered.
[0047]
When adding water, it is preferable to use together alkaline substances, such as sodium hydroxide, as a neutralizer of a (meth) acrylic acid component. By adding an alkaline substance, the cross-linking reaction between the cyclic amide monomer / (meth) acrylic acid polymer and the aluminum compound proceeds more favorably, and the solubility and increase of the cyclic amide monomer / (meth) acrylic acid polymer are improved. It also contributes to the improvement of viscosity.
[0048]
Examples of the alkaline substance that can be used in the present invention include alkali metal hydroxides, alkaline earth metal hydroxides, primary, secondary or tertiary alkylamines, or primary and secondary. Grade or tertiary alkanolamine, etc.,
Specifically, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonia, aqueous ammonia, triethanolamine, dimethylamine, diethylamine, trimethylamine, triethylamine, triisopropanolamine, trisodium phosphate, phosphoric acid Examples thereof include disodium hydrogen, dipotassium hydrogen phosphate, monoethanolamine, diethanolamine, diisopropanolamine, and polyethanolamine. Among these, sodium hydroxide, aqueous ammonia, triethanolamine, and diisopropanolamine are preferable from the viewpoint of irritation to the skin.
[0049]
The said alkaline substance is added in 0.01-20 mass% with respect to the whole quantity of a hydrophilic adhesive composition, Preferably it is added in 0.05-10 mass%.
[0050]
It is preferable to add an acid to the hydrophilic pressure-sensitive adhesive composition of the present invention as a crosslinking reaction rate adjusting agent. Examples of the acid used in the present invention include tartaric acid, citric acid, lactic acid, glycolic acid, malic acid, salicylic acid, fumaric acid, methanesulfonic acid, maleic acid, acetic acid and other organic acids, EDTA-2 sodium, urea, triethylamine In addition to organic acids having chelating or coordination ability to metal ions such as ammonia, organic acid salts thereof, inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, hydrobromic acid, etc. . Among these, organic acids are preferable, and oxycarboxylic acids such as tartaric acid, citric acid, lactic acid, glycolic acid, malic acid, and gluconic acid having both a hydroxyl group and a carboxyl group in one molecule are particularly preferable.
[0051]
The acid is preferably added in an amount of 5% by mass or less based on the total amount of the hydrophilic pressure-sensitive adhesive composition.
[0052]
Other polymer compounds may be added to the hydrophilic pressure-sensitive adhesive composition of the present invention for the purpose of improving the shape retention of the pressure-sensitive adhesive layer. Examples of such a polymer compound include N-vinylacetamide such as polyvinylpyrrolidone, carboxyvinyl polymer which is a crosslinked polyacrylic acid, vinylpyrrolidone-ethyl acrylate copolymer, N-vinylacetamide-sodium acrylate copolymer, and the like. Copolymers, N-vinylacetamide homopolymers, polyvinylsulfonic acid, N-vinylacetamide cross-linked products, polyitaconic acid, hydroxypropylcellulose, hydroxypropylmethylcellulose and the like.
[0053]
The polymer compound is added in a range of 0.1 to 20% by mass, preferably in a range of 1 to 10% by mass with respect to the total amount of the hydrophilic pressure-sensitive adhesive composition. When the amount of the polymer compound added is less than 0.1% by mass, sufficient shape retention is not achieved, and when it exceeds 20% by mass, the adhesive layer becomes hard and the feeling of adhesion to the skin deteriorates, resulting in a medicinal effect. Absorbability of components may be inferior.
[0054]
Although it does not specifically limit as an active ingredient (component D) which can be administered using the hydrophilic adhesive composition of this invention, For example, the following are mentioned.
(A) Corticosteroids: Specifically, hydrocortisone, prednisone, beclomethasone pyropionate, flumethasone, triamcinolone, triamcinolone acetonide, fluocinolone, fluocinolone acetonide, fluocinolone acetonide acetate, clobetasol propionate, etc. .
(B) Anti-inflammatory analgesic: specifically salicylic acid, glycol salicylate, methyl salicylate, 1-menthol, camphor, sulindac, trimethine sodium, naproxen, fenbufen, piroxicam, triamcinolone, hydrocortisone acetate, indomethacin, ketoprofen, acetaminophen , Mefenamic acid, flufenamic acid, ibufenac, loxoprofen, thiaprofen, pranoprofen, fempfen, diclofenac, diclofenac sodium, alclofenac, lornoxicam, mepranoprofen, oxyphenbutazone, ibuprofen, ferpinac, ketronac, vermoprofen, Napumeton, naproxen, flurbiprofen, fluocinonide, clobetazopropionate , COX-2 inhibitors (nimesulide, such as meloxicam), and the like.
(C) Antifungal agents: specifically clotrimazole, tolnaftate, econazole nitrate, omoconazole nitrate, thioconazole nitrate, ketoconazole nitrate, miconazole nitrate, isoconazole nitrate, tolnaftate, thioconazole nitrate, sulconazole nitrate, pyrrolnitrin, bimafucin, Undecylenic acid, salicylic acid, siccanin, nystatin, nornaphthate, exalamide, phenyliodoundecinoeha, thianthol, cyclopyroxolamine, haloprozin, tricomycin, variotin, pentamycin, amphotericin B and the like.
(D) Antihistamine: Specifically, tetracycline hydrochloride, diphenhydramine hydrochloride, chlorpheniramine, diphenylimidazole, chloramphenicol and other antibiotics, diphenhydramine, chlorpheniramine maleate and the like.
(E) Hypnotic sedative: Specifically, phenobarbital, amobarbital, cyclobarbital, lorazepam, haloperidol and the like.
(F) Tranquilizer: Specifically, fluphenazine, theoridazine, diazepam, flunitrazepam, chlorpromazine and the like.
(G) Antihypertensive agents: Specifically, clonidine, clinidine hydrochloride, pindolol, propranolol, propranolol hydrochloride, bufuranol, indenolol, bucmolol, nifedipine and the like.
(H) Antihypertensive diuretics: specifically, hydrothiazide, bendrofluthiazide, cyclopenthiazide and the like.
(I) Antibiotics: Specifically, penicillin, tetracycline, oxytetracycline, fradiomycin sulfate, erythromycin, chloramphenicol and the like.
(J) Anesthetic agent: Specifically, lidocaine, benzocaine, ethyl aminobenzoate, dibucaine and the like.
(K) Antibacterial substances: Specifically, benzalkonium chloride, nitrofurazone, nystatin, acetosulfamine, clotrimazole and the like.
(L) Vitamin preparation: Specifically, vitamin A, ergocalciferol, cholecalciferol, octothiacin, riboflavin butyrate and the like.
(M) Antiepileptic agents: Specifically, nitrozepam, mepropamate, clonazepam and the like.
(N) Coronary vasodilator: Specifically, tulobuterol, nitroglycerin, nitroglycol, isosorbidinitrate, erythritol tetranitrate, pentaerythritol tetranitrate, propatyl nitrate, and the like.
(O) Antihistamine: Specifically, diphenhydramine hydrochloride, chlorpheniramine, diphenylimidazole and the like.
(P) Antitussive: Specifically, dextromethorphan, terbutamine, ephedrine, ephedrine hydrochloride and the like.
(Q) Sex hormone: Specifically, progesterone, estradiol and the like.
(R) Antidepressant: Specifically, doxepin and the like.
(S) Angina treatment agent: Specifically, antiperspirants such as diethylamide and camphor, nitroglycerin, isosorbide nitrate and the like.
(T) Narcotic analgesics: Specifically, morphine hydrochloride, ethyl morphine hydrochloride, morphine sulfate, cocaine hydrochloride, pethidine hydrochloride, codeine phosphate, dihydrocodeine phosphate, fentanyl citrate, sufentanil, meperidine hydrochloride and the like.
(U) Herbal medicines: specifically, Aoba, Ohi, Onji, Gajutsu, Chamomile, Caronin, Daylily, Kyokyo, Kyonin, Gooh, Garbage, Pikachi, Psycho, Saishin, Syazenshi, Shouma, Senega, Sojutsu, Sakuhaku, Chouji Chimpi, Tokon, Nantenjitsu, Baimo, Bakumondo, Hange, Beaked Jutsu, Hiyos, Bowhou, Maou etc.
(V) Others: Oxybutynin, 5-fluorouracil, dihydroergotamine, fentanyl, desmopressin, digoxin, metoclopracid, domperide, scopolamine, scopolamine hydrobromide, etc., veterinary drugs, hypnotics, cardiovascular drugs, brain Metabolic stimulant, bactericidal agent, enzyme preparation, enzyme inhibitor, biopharmaceutical (polypeptide), keratosis treatment agent, narcotic, antineoplastic agent, general anesthetic agent, anxiolytic agent, asthma / nasal allergic agent, anti-parkinsonian Agent, chemotherapeutic agent, anthelmintic agent, antiprotozoal agent, hemostatic agent, cardiotonic agent, stimulant / stimulant agent, addictive addiction agent, Chinese medicine, radiopharmaceutical, urogenital organ, anal agent, hypoglycemic agent, antiulcer agent Examples include hair preparations, sequestering agents, antiperspirants, tranquilizers, antistimulating agents, antirheumatics, antigout agents and anticoagulants. . These medicinal components may be used alone or in combination of two or more.
[0055]
The medicinal component is desirably blended in the range of 0.01 to 30% by mass, preferably in the range of 2 to 20% by mass with respect to the total amount of the hydrophilic pressure-sensitive adhesive composition.
[0056]
The medicinal component can be included after the solution stage (or gel suspension stage) or after aging for the crosslinking reaction. The method of inclusion may be appropriately performed according to the initial purpose for the physical properties, administration site and release rate of the medicinal component.
[0057]
You may add the adjuvant which accelerates | stimulates absorption of these medicinal ingredients to the hydrophilic adhesive composition of this invention. As an auxiliary agent that can be used in the present invention, for example,
Alcohols such as ethyl alcohol, isopropyl alcohol, butanol, polyethylene glycol # 400, benzyl alcohol, phenylethyl alcohol, hexyl decanol, propanol;
Higher alcohols such as oleyl alcohol, stearyl alcohol, lauryl alcohol;
Keratin softeners such as urea and sulfur;
Humectants such as pyrrolidone carboxylic acid;
Surfactants such as propylene glycol monooleate, polyoxyethylene sorbitan monostearate, sorbitan monostearate, glycerin monostearate;
Esters such as isopropyl myristate and diethyl sebacate;
Fatty acids such as stearic acid, hexanoic acid, nonanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, octadecanoic acid, oleic acid, linoleic acid;
Terpene compounds such as menthol, menthone, limonene, pinene, piperiton, terpinene, terpinolene, terpinolol, carpeol;
Auxiliary agents such as allantoin, diisopropyl adipate, diethyl sebacate, ethyl laurate, lanolin, aison;
Refreshing agents such as menthol and camphor;
Almond oil, olive oil, camellia oil, persic oil, peppermint oil, sesame oil, soybean oil, mink oil, cottonseed oil, corn oil, safflower oil, coconut oil, eucalyptus oil, castor oil, liquid paraffin, petrolatum, squalene, squalane, lanolin Oil components such as;
Gelling agents such as carboxyvinyl polymers;
Neutralizing agents such as diisopropanolamine; and
Examples of other compounds include crotamiton, propylene carbonate, 1-geranyl azasilroheptan-2-one (GACH), fatty acid dialkyrolamide, salicylic acid, and salicylic acid derivatives.
[0058]
The above adjuvants can be blended alone or in combination of two or more. However, in consideration of skin irritation and the like, the blending amount of the adjuvant is based on 100 parts by mass of the hydrophilic adhesive composition. 0.1 to 5 parts by mass is desirable.
[0059]
In the pressure-sensitive adhesive composition of the present invention, depending on the purpose such as increasing the characteristics, improving the processing / moldability and quality, and improving the dispersibility and stability of the medicinal component in the pressure-sensitive adhesive composition. In addition, the following additives can be arbitrarily blended to such an extent that the performance of the pressure-sensitive adhesive is not impaired.
(1) Wetting agent: For example, dl-pyrrolidone carboxylic acid, sodium lactate and the like.
(2) Astringents: for example, aluminum chloride, aluminum sulfate, allantochlorohydroxyaluminum, allantoindihydroxyaluminum, aluminum phenolsulfonic acid, zinc paraphenolsulfonate, zinc sulfate, aluminum chlorohydroxide and the like.
(3) Moisturizer: NMF components such as sodium lactate, water-soluble polymers such as hyaluronic acid, collagen, mucopolysaccharide, chondroitin sulfate, etc.
(4) Thickener: For example, gum arabic, tragacanth gum, locust bean gum, guar gum, echo gum, karaya gum, agar, starch, carrageenan, alginic acid, alginates (specifically sodium alginate), propylene glycol alginate, dextran, Natural high molecular compounds such as dextrin, amylose, gelatin, collagen, pullulan, pectin, amylopectin, starch, amylopectin sodium semiglycolate, chitin, albumin, casein;
Polyglutamic acid, polyaspartic acid, methylcellulose, ethylcellulose, propylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylstarch, alkali metal carboxymethylcellulose, alkali metal cellulose sulfate, cellulose graft polymer, crosslinked gelatin Semi-synthetic polymer compounds such as cellulose acetate phthalate, starch-acrylic acid graft polymerization, phthalic anhydride modified gelatin, succinic acid modified gelatin;
Polyvinyl alcohol, polyvinyl pyrrolidone, vinyl methyl ether / maleic anhydride copolymer, carboxy vinyl polymer, vinyl pyrrolidone-ethyl acrylate copolymer, vinyl pyrrolidone-styrene copolymer, vinyl pyrrolidone-vinyl acetate copolymer, vinyl acetate -N-vinylacetamide copolymers such as (meth) acrylic acid copolymer, polyvinyl acetate-crotonic acid copolymer, N-vinylacetamide-sodium acrylate copolymer, polyvinyl sulfonic acid, N-vinylacetamide cross-linked , Polyitaconic acid, polyhydroxyethyl acrylate, polyacrylamide, styrene-maleic anhydride copolymer, acrylamide-acrylic acid copolymer, vinyl acetate- (meth) acrylic acid copolymer, vinyl acetate-croto Polymeric compounds such as the synthesis of such acid copolymers.
(5) Tackifying substance: For example, various sticky substances such as silicone rubber, polyisobrengon, styrene-block copolymer rubber, acrylic rubber, and natural rubber.
(6) Antidiarrheal agents: For example, camphor, thymol, menthol, polyoxyethylene lauryl ether, antihistamine, ethyl aminobenzoate and the like.
(7) Keratin softening release agent: for example, sulfur, thioxolone, selenium sulfide, salicylic acid, resorcin.
(8) Incorrect eating prevention substances: for example, chili powder, red pepper essence, etc.
(9) Powder raw materials: For example, montmorillolate, anhydrous silicic acid, gypsum, carbon black, diatomaceous earth, bengara, calcium carbonate, hydrotalcite, talc, glass, kaolin, bentonite, metal soap, aerosil, mica titanium, Bismuth oxychloride, fish scale foil, zinc white, titanium dioxide, etc.
(10) Oily raw materials: For example, almond oil, olive oil, hydrogenated oil, camellia oil, castor oil, owl oil, coconut oil, beeswax, whale wax, lanolin, carnauba wax, candelilla wax, liquid paraffin, petrolatum, microcrystalline wax, Ceresin, squalene, lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, oleic acid, lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, octyldodecanol, cholesterol, hexyldecanol, wite sterol, cetyl lactate, isopropyl myristate , Hexyl laurate, myristyl myristate, isopropyl palmitate, octyldodecanol myristate, butyl stearate, cacao oil, tree wax, jojoba oil, gray Pseed oil, avocado oil, mink oil, egg yolk oil, beeswax, whale wax, lanolin, carnauba wax, candelilla wax, liquid paraffin, ceresin wax, paraffin wax, behenic acid, isopropyl adipate, octyldodecyl myristate, octyl oleate Dodecyl, cholesterol oleate, etc.
(11) Surfactant: For example, lauryl sulfate ester salt, polyoxyethylene alkyl ether sulfate, alkyl benzene sulfonate, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl phenyl ether phosphate, N-acyl amino acid salt, Anionic surfactants such as sodium stearate, potassium palmitate, sodium cetyl sulfate, sodium lauryl sulfate, triethanolamine palmitate, sodium polyoxyethylene lauryl phosphate, sodium acylglutamate, surfactin;
Cationic surfactants such as benzalkonium chloride, benzethonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride;
Amphoteric surfactants such as alkyldiaminoethylglycine hydrochloride, 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryldimethylaminoacetic acid betaine, lecithin;
Polyol fatty acid ester, glyceryl monostearate, glyceryl monooleate, ethylene glycol monostearate, propylene glycol monostearate, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene alkyl Ether, polyoxyethylene alkylphenol ether, polyoxyethylene sorbitol fatty acid ester, N-acyl amino acid ester, sucrose fatty acid ester, fatty acid alkylolamide, polyoxyethylenated sterol, polyoxyethylenated lanolin, polyoxyethylene hydrogenated castor oil, etc. Nonionic surfactants, etc.
(12) Colorant: For example, yellow iron oxide, red iron oxide, black iron oxide, ultramarine, carbon black, chromium hydroxide, chromium oxide, tar dye, lake, red No. 2, red No. 3, red No. 102, red No. 201 Yellow No. 4, Yellow No. 5, Blue No. 1, Blue No. 2, etc.
(13) Fragrance: For example, palm oil, orange oil, pepper oil, jasmine oil, cedar oil, ginger oil, terpin oil, orange flower oil, rose oil, eucalyptus oil, lime oil, lemon oil, Japanese mint oil, rose Vegetable fragrances such as mary oil; animal fragrances such as musk, reibiko, kairikou and rysenkou; hydrocarbon fragrances such as bromostyrol, pinene and limonene; alcoholic fragrances such as benzyl alcohol and l-menthol; Ester-based fragrances such as methyl; aldehyde-based fragrances such as benzaldehyde and salicylaldehyde; ketone-based fragrances such as camphor, muscone, musk ketone and l-menton; ether-based fragrances such as safrole; Lactones perfume; acid perfume such as phenylacetic acid; Nitrogen compound-based perfumes such as Ndoru.
(14) UV blocking agent: for example, ASL-24TM, Cyasorb UV-9TM, Uvinul M-40TMBenzophenone series; SalolTMBenzoic acid series such as Tinuvin PTMAzoles such as Uvinul N-35TMNitriles such as Ancour UATMUrea system such as Neo Heliopan Give tan FTMPara-amino acids such as 2-hydroxy-4-methoxybenzophenone, octyldimethylparaaminobenzoate, ethylhexylparamethoxycynamate, salicylic acid, benzofuran, coumarin, azole and the like.
(15) Antiseptic fungicides: for example, organic acids such as benzoic acid, salicylic acid, dehydroacetic acid, sorbic acid, acrylic acid, methacrylic acid; phenols such as paraoxybenzoic acid ester, phenoxyethanol, thymol, hinokitiol, thioxolone; hexachlorophene, Halogenated bisphenols such as 2,4,4′-trichloro-2′-hydroxydiphenyl ether; amide compounds such as trichlorocarbanilide, halocarban, udesylenic acid monoethanolamide; benzalkonium chloride, alkyl isocyanate Quaternary ammonium compounds such as norinium, benzethonium chloride, cetylpyridinium chloride; amphoteric surfactants such as lauryl di (aminoethyl) glycine; 2-pyridinethiol-1-oxide zinc salt, gluconic acid, Hekishijin, thiram, N- trichloromethylthio-4-cyclohexene -1.2- dicarboximide, chlorobutanol, and the like.
(16) Antioxidants: For example, nordihydroguaiaretic acid, guaiac fat, propyl gallate, butylhydroxyanisole, dibutylhydroxytoluene (BHT), tocopherol (vitamin E), 2,2′-methylenebis (4-methyl) -6-tert-butyl) phenol and the like.
(17) Chelating agent: for example, edetate, pyrophosphate, hexametaphosphate, etc.
(18) Ultraviolet scattering agent: For example, titanium oxide, kaolin, talc and the like.
[0060]
In addition to the above, stabilizers, fillers, preservatives, plasticizers, softeners, deterioration inhibitors and the like may be added, and these additives do not affect the properties of the resulting hydrophilic pressure-sensitive adhesive composition. Can be added arbitrarily in the range.
[0061]
As described above, an acid and an alkaline substance can be used for the hydrophilic pressure-sensitive adhesive composition of the present invention, but the pH of the final pressure-sensitive adhesive composition is adjusted in order to reduce irritation to the skin and the like. There is a need.
[0062]
The pH adjuster that can be used in the present invention is not particularly limited, and examples thereof include sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammore, aqueous ammonia, triethanolamine, dimethylamine, diethylamine, Alkali metal hydroxides such as trimethylamine, triethylamine, triisopropanolamine, trisodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, monoethanolamine, diethanolamine, diisopropanolamine, polyethanolamine, alkaline earth metals Hydroxides, primary, secondary or tertiary alkylamines, or alkalis such as primary, secondary or tertiary alkanolamines, or citric acid, tartaric acid, lactic acid, glycolic acid, Hydrochloric acid, glass , Malic acid, acids such as phosphoric acid.
[0063]
In addition, a polymer compound showing acidity or alkalinity can be used, for example, alginic acid, polyglutamic acid, polyaspartic acid, starch-acrylic acid graft polymer, polyacrylic acid, polyvinyl acetate-crotonic acid copolymer, vinyl acetate. -(Meth) acrylic acid copolymer, vinyl acetate-crotonic acid copolymer, polyvinyl sulfonic acid, polyitaconic acid, styrene-maleic anhydride copolymer, acrylamide-acrylic acid copolymer and the like.
[0064]
Since the hydrophilic pressure-sensitive adhesive composition of the present invention has excellent properties, it can be applied to various uses as described below.
(I) Pharmaceuticals: For example, patches such as transdermal absorption preparations, transmucosal absorption preparations, and the like.
(Ii) Cosmetics, quasi-drugs: for example, packs, acne supplies, etc.
[0065]
In order to use for the above-mentioned applications, the hydrophilic pressure-sensitive adhesive composition of the present invention is directly mixed with various raw materials and then poured into an appropriate mold in a sol state, where it is crosslinked and molded, or after crosslinking. The gel is prepared into various molded articles using an appropriate molding machine, tableting machine and the like.
[0066]
The mixing of the raw materials can be performed, for example, by appropriately selecting and using a kneader, a kneader, a kneader ruder, an azimuth homomixer, a planetary mixer, a double planetary mixer, and the like.
[0067]
In order to form the hydrophilic pressure-sensitive adhesive composition of the present invention into a sheet, paper, wood, metal, glass fiber, cloth (nel, woven cloth, non-woven cloth, etc.), synthetic resin (polyurethane, ethylene vinyl acetate copolymer, polychlorinated) Vinyl, polyester, polyolefin, polyamide, polyvinylidene chloride, polytetrafluoroethylene, etc.), metal foils such as aluminum, molded articles such as rubber or cellulose derivatives and laminated films of these with plastic films, sheets (foil), or tapes An appropriate amount of a hydrophilic pressure-sensitive adhesive may be applied to one or both surfaces of the support.
[0068]
In order to facilitate the storage of the obtained sheet-like hydrophilic pressure-sensitive adhesive, a release sheet treated with silicon or other suitable method is stuck on the surface coated with the hydrophilic pressure-sensitive adhesive, Alternatively, the surface to which the hydrophilic adhesive is not applied is treated with silicon or other suitable method to form a release surface, and the surface to which the hydrophilic adhesive is applied and the release surface to which the hydrophilic adhesive is not applied overlap. It is desirable to wind or pile up. As the release sheet, polyethylene film, polypropylene film, release paper, cellophane, polyvinyl chloride, polyester and the like are used.
[0069]
【The invention's effect】
The hydrophilic pressure-sensitive adhesive composition of the present invention comprises a cyclic amide monomer / (meth) acrylic acid copolymer and a medicinal component dispersed or dissolved in a high-concentration polyhydric alcohol. The polyhydric alcohol can be contained, and the stable adhesion layer which does not leave | separate can be formed. In addition, a patch using a hydrophilic adhesive composition has excellent release characteristics and adhesiveness, and has high safety.
[0070]
【Example】
EXAMPLES Hereinafter, although this invention is demonstrated further more concretely based on an Example, this invention is not limited to these Examples. In addition, “parts” in this example means parts by mass.
<Example of production of N-vinyl-pyrrolidone / acrylic acid copolymer>
A three-necked separable flask was equipped with a stirrer and a condenser, and charged with 42 g of N-vinylpyrrolidone, 18 g of acrylic acid, and 540 g of ethyl acetate. Further, 0.3 g of dimethyl 2,2'-azobis (2-methylpropionate) was added and heated to the boiling point of ethyl acetate. As the polymerization progressed, a precipitate precipitated from the homogeneous solution. The polymerization reaction was performed for 5 hours, and after cooling, it was filtered. The obtained precipitate was vacuum-dried and crushed to obtain a finely divided N-vinylpyrrolidone / acrylic acid copolymer.
[0071]
The copolymer obtained as described above is dissolved in a mixture of isopropanol / water = 1/1 (volume ratio) to make a 10% by mass solution, and 10% by mass sodium hydroxide solution is added to this solution. The viscosity of the solution obtained by neutralizing the acrylic acid portion of the copolymer was 200 mPa · s (25 ° C.).
[0072]
[Example 1]
(Combination)
10 parts of N-vinyl-pyrrolidone / acrylic acid copolymer (80/20 weight ratio)
88 parts glycerin
Magnesium aluminate metasilicate 1 part
Tulobuterol 1 copy
(Prescription)
After gradually adding 10 parts of N-vinylpyrrolidone / acrylic acid copolymer (80/20 weight ratio) to a mixed solution consisting of 70 parts of glycerin and 1 part of magnesium metasilicate, 18 parts of glycerin and tulobuterol 1 While slowly adding a mixture of parts, it was mixed until uniform.
[0073]
The obtained sol was molded and sealed, and the gel obtained by aging at about 20 ° C. for 3 days had stretchability and strong repulsion.
[0074]
[Example 2]
(Combination)
N-vinyl-3-methylpyrrolidone / methacrylic acid copolymer
(50/50 weight ratio) 3 parts
N-methyl-2-pyrrolidone 7 parts
79.5 parts propylene glycol
0.5 parts of magnesium aluminate silicate
N-vinylacetamide / sodium acrylate copolymer
(90/10 weight ratio) 5 parts
5 parts of oxybutynin
(Prescription)
In a mixed solution consisting of 79.5 parts of propylene glycol and 0.5 part of magnesium aluminate silicate, 3 parts of N-vinyl-3-methylpyrrolidone / methacrylic acid copolymer (50/50 weight ratio) and N-vinylacetamide -After gradually adding 5 parts of sodium acrylate copolymer (90/10 weight ratio), the mixture was uniformly added while slowly adding a mixture of 7 parts of N-methyl-2-pyrrolidone and 5 parts of oxybutynin. Mix until.
[0075]
The obtained sol was molded and sealed, and the gel obtained by aging at about 20 ° C. for 3 days had stretchability and strong repulsion.
[0076]
[Example 3]
(Combination)
N-vinyl-5-methylpyrrolidone / acrylic acid copolymer
(20/80 weight ratio) 5 parts
30 parts glycerin
1,3-butylene glycol 19.2 parts
40 parts purified water
Carboxy vinyl polymer 2 parts
0.4 parts of dry aluminum hydroxide gel
Tartaric acid 0.6 parts
Sodium hydroxide 1.8 parts
Diclofenac sodium 1 part
(Prescription)
To a solution composed of 1.8 parts of sodium hydroxide and 20 parts of purified water, a mixed solution consisting of 5 parts of N-vinyl-5-methylpyrrolidone / acrylic acid copolymer (20/80 weight ratio) and 30 parts of glycerin was added. Kneaded until uniform. Next, 19.2 parts of 1,3-butylene glycol, 2 parts of carboxyvinyl polymer (Carbopol 934: NOVEON), 1 part of diclofenac sodium and 0.4 parts of dry aluminum hydroxide gel (manufactured by Kyowa Chemical Industry Co., Ltd.) While gradually adding a mixed solution consisting of, kneaded until uniform, and further, a solution consisting of 0.6 parts of tartaric acid and 20 parts of purified water was added at once and kneaded.
[0077]
The obtained sol was molded and sealed, and the gel obtained by aging at about 20 ° C. for 3 days had stretchability and strong repulsion.
[0078]
[Example 4]
(Combination)
N-vinyl-caprolactam / acrylic acid copolymer
(40/60 weight ratio) 8 parts
Hydroxypropylcellulose 3 parts
Lactic acid 1 part
1 part of dihydroxyaluminum aminoacetate
55.5 parts triethylene glycol
N-vinylacetamide cross-linked product 2 parts
30 parts of purified water
10 parts of N-ethyl-2-pyrrolidone
0.5 parts diisopropanolamine
Indomethacin 1 part
(Prescription)
In a solution consisting of 0.5 parts of diisopropanolamine and 20 parts of purified water, 8 parts of N-vinyl-caprolactam / acrylic acid copolymer (40/60 weight ratio), 1 part of dihydroxyaluminum aminoacetate and triethylene glycol 55. A mixed solution of 5 parts was added and kneaded until uniform. Next, a mixed solution consisting of 10 parts of N-ethyl-2-pyrrolidone, 2 parts of N-vinylacetamide crosslinked product and 1 part of indomethacin was gradually added and kneaded, and further a solution consisting of 1 part of lactic acid and 10 parts of purified water. And kneaded until uniform.
[0079]
The obtained sol was molded and sealed, and the gel obtained by aging at about 20 ° C. for 3 days had stretchability and strong repulsion.
[0080]
[Reference example]
(Combination)
N-vinyl-3-methylpyrrolidone / methacrylic acid copolymer
(95/5 weight ratio) 3 parts
N-methyl-2-pyrrolidone 7 parts
79.5 parts propylene glycol
0.5 parts of magnesium aluminate silicate
N-vinylacetamide / sodium acrylate copolymer
(90/10 weight ratio) 5 parts
5 parts of oxybutynin
(Prescription)
In a mixed solution consisting of 79.5 parts of propylene glycol and 0.5 part of magnesium aluminate silicate, 3 parts of N-vinyl-3-methylpyrrolidone / methacrylic acid copolymer (95/5 weight ratio) and N-vinylacetamide -It melt | dissolved, adding 5 parts of sodium acrylate copolymers (90/10 weight ratio) gradually. Subsequently, it mixed until it became uniform, adding slowly the liquid mixture which consists of 7 parts of N-methyl- 2-pyrrolidone and 5 parts of oxybutynins.
[0081]
The gel obtained by molding and sealing the obtained sol and aging at about 20 ° C. for 3 days was slightly weak in repulsive force, and when touched, the liquid exuded slightly from the gel.
[0082]
[Comparative Example 1]
(Combination)
10 parts of polyacrylic acid
88 parts glycerin
Magnesium aluminate metasilicate 1 part
Tulobuterol 1 copy
(Prescription)
Polyacrylic acid (10 parts) was gradually added and dissolved in a mixed solution consisting of 70 parts of glycerin and 1 part of magnesium metasilicate. Subsequently, it mixed until it became uniform, adding slowly the liquid mixture which consists of 18 parts of glycerol and 1 part of tulobuterol.
[0083]
The obtained sol was molded and sealed, and the gel obtained by aging at about 20 ° C. for 3 days had no repulsive force. When touched, glycerin exudes and the sol adhered to the finger.
Claims (11)
メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウム、水酸化アルミニウムおよびジヒドロキシアルミニウムアミノアセテートからなる群より選ばれる少なくとも1種のアルミニウム化合物と、
多価アルコールとを含み、前記共重合体における前記式(I)で表される繰り返し単位と前記式(II)で表される繰り返し単位との共重合比が重量比で80/20〜20/80であることを特徴とする親水性粘着剤組成物;
At least one aluminum compound selected from the group consisting of magnesium aluminate metasilicate, magnesium aluminate silicate, aluminum hydroxide and dihydroxyaluminum aminoacetate ;
Look containing a polyhydric alcohol, the co said in the polymer formula in copolymerization ratio is the weight ratio of the repeating unit represented by the repeating unit and the formula (II) represented by (I) 80 / 20~20 / 80, a hydrophilic pressure-sensitive adhesive composition,
メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウム、水酸化アルミニウムおよびジヒドロキシアルミニウムアミノアセテートからなる群より選ばれる少なくとも1種のアルミニウム化合物と、
多価アルコールとを含み、前記共重合体における前記環状アミドモノマーと前記(メタ)アクリル酸との共重合比が重量比で80/20〜20/80であることを特徴とする親水性粘着剤組成物;
At least one aluminum compound selected from the group consisting of magnesium aluminate metasilicate, magnesium aluminate silicate, aluminum hydroxide and dihydroxyaluminum aminoacetate ;
Look containing a polyhydric alcohol, a hydrophilic adhesive, wherein the copolymerization ratio of the cyclic amide monomer and the (meth) acrylic acid in the copolymer is 80 / 20-20 / 80 by weight ratio Agent composition;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003176384A JP4350435B2 (en) | 2003-06-20 | 2003-06-20 | Hydrophilic adhesive composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003176384A JP4350435B2 (en) | 2003-06-20 | 2003-06-20 | Hydrophilic adhesive composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005008585A JP2005008585A (en) | 2005-01-13 |
JP4350435B2 true JP4350435B2 (en) | 2009-10-21 |
Family
ID=34099279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003176384A Expired - Fee Related JP4350435B2 (en) | 2003-06-20 | 2003-06-20 | Hydrophilic adhesive composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4350435B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102257116B1 (en) * | 2021-03-31 | 2021-05-27 | (주)블루트레이더스 | Laminated heat sink with improved thermal conductivity |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7038091B2 (en) * | 2019-09-30 | 2022-03-17 | 三菱製紙株式会社 | Adhesive sheet |
-
2003
- 2003-06-20 JP JP2003176384A patent/JP4350435B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102257116B1 (en) * | 2021-03-31 | 2021-05-27 | (주)블루트레이더스 | Laminated heat sink with improved thermal conductivity |
Also Published As
Publication number | Publication date |
---|---|
JP2005008585A (en) | 2005-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI412570B (en) | Adhesive for patch and method for producing the same | |
DE60320251T2 (en) | AQUEOUS GEL AND METHOD OF PREPARATION AND USE OF THE AQUEOUS GEL | |
JPH04182437A (en) | Base or adjuvant of medicine for external use and medicine containing the same for external use in human or animal | |
CN104188942A (en) | Transdermal absorption promoter, and external skin formulation thereof | |
TWI344850B (en) | ||
JP4693340B2 (en) | Hydrous gel body, method for producing the hydrogel body, and use thereof | |
JP2006321792A (en) | Water-bearing gel and its production method | |
JPH08243377A (en) | Alcohol-containing gel body | |
JP5175041B2 (en) | Hydrophilic adhesive, hydrophilic external skin adhesive composition and hydrophilic patch using the same | |
JP2001151973A (en) | Alkaline hydrous gel | |
JP2007119552A (en) | Method for producing (meth)acrylic acid based water-containing gel form and (meth)acrylic acid based water-containing gel form | |
JP3914241B2 (en) | Adhesive for patch and method for producing the same | |
JP4350435B2 (en) | Hydrophilic adhesive composition | |
JPH10265373A (en) | Tacky adhesive composition and poultice | |
JP2004168764A (en) | Adhesive composition for patch preparation and method for producing the same | |
WO2006112533A1 (en) | Water-containing gel form and production method thereof | |
JP4290626B2 (en) | Skin external material | |
US20100055156A1 (en) | Composition for the topical transmission of active ingredients into the human or animal body | |
JP2002020316A (en) | Percutaneous absorbefacient, trans mucosa absorbefacient | |
JP2000053528A (en) | Skin-applying agent composition | |
JPH0797317A (en) | Film-forming agent for external use | |
JP4171305B2 (en) | Packing agent using water-soluble nonwoven fabric | |
JP2004026747A (en) | Exothermic cataplasm | |
Antunes | State-Of-Art on Gel Technologies for Transdermal Delivery of Bacitracin | |
JPS5869248A (en) | Alcohol gel composition for external application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090414 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090714 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090722 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120731 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |